

List of tables

Table 1 Study characteristics for randomised controlled trials reporting safety outcomes

2

Table 2 Additional study characteristics for randomised controlled trials reporting safety outcomes

53

Table 1 Study characteristics for randomised controlled trials reporting safety outcomes

Study	Study Sponsor	Study Design	Study Duration (weeks)	Duration of Drug Treatment (weeks)	Location	Willing to Quit?	Smokeless Tobacco?	Total N	Females N (%)	White %	Study Arms
Abelin 1989¹		Parallel RCT	52	12	Switzerland	Yes	No	199	80 (40)		1. NRT Patch (24hrs) 2. Placebo
Ahluwalia 1998²	American Cancer Society Career, Marion Merrell Dow, Inc., Emory Medical Care Foundation	Parallel RCT	24	10	Georgia, USA	Yes	No	410	267 (65)	0	1. NRT Patch (24hrs) High 2. Placebo
Ahluwalia 2002³	National Cancer Institute	Parallel RCT	27	7	USA	Yes	No	600	420 (70)	0	1. Bupropion Standard + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling
AKIA401⁴	GSK	Parallel RCT	52	12	USA	Yes	No	52	0 (0)	87	1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling
Allen 2011⁵	Supported by Projet Recherche Developpement 06-II-21, Hospital of the University of Geneva (Dr. Damsa), and an Independent Investigator Award, National Alliance for Research on Schizophrenia and Depression (Dr. Allen)	Parallel RCT	0.14	0.14	Geneva, Switzerland	Not necessarily motivated to quit	No	40			1. NRT Patch (24hrs) High 2. Placebo
Andrews 2016⁶	National Health, Lung & Blood Institute of the National Institutes of Health	Cluster RCT	52	8	Georgia and South Carolina, USA	Yes	No	409	409 (100)		1. NRT Patch (24hrs) + Individual + Group Long Counselling 2. Waitlist
Anthenelli 2013⁷	Pfizer	Parallel RCT	52	12	USA (9 centres) and 24 centres across Bosnia & Herzegovina, Croatia, Germany,	Yes	No	525	329 (63)		1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling

						Hungary, Romania, Russian Federation, Spain					
Anthenelli 2016A⁸	Pfizer and GlaxoSmithKli ne	Parallel RCT	52	12	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico, New Zealand, Russian Federation, Slovakia, South Africa, Spain, USA	Yes	No	4028	1985 (49)	83	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. Placebo + Individual Short Counselling
Anthenelli 2016B⁸	Pfizer and GlaxoSmithKli ne	Parallel RCT	52	12	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico, New Zealand, Russian Federation, Slovakia, South Africa, Spain, USA	Yes	No	4116	2524 (61)	81	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. Placebo + Individual Short Counselling
Anthonisen 1994⁹	Division of Lung Diseases of the National Heart, Lung, and Blood Institute. The Salt Lake City Center: National Center for Research Resources	Parallel RCT	754	24	Baltimore, Birmingham, Cleveland, Detroit, Los Angeles, Pittsburgh, Portland, Rochester, Salt Lake City, USA and Winnipeg, Canada	Yes	No	5887	2178 (37)	95	1. NRT Gum Standard 2. Usual Care (Three arms collapsed into two arms)
Areechon 1988¹⁰	Merrell Dow (Bangkok,	Parallel RCT	24	12	Thailand	Yes	No	200	11 (6)		1. NRT Gum Standard 2. Placebo

	Thailand) and A.B. Leo, Helsingborg, Sweden										
Aubin 2004¹¹	GlaxoSmithKline (GSK) France	Parallel RCT	26	7	France	Yes	No	506	280 (56)		1. Placebo + Individual + Telephone Short Counselling 2. Bupropion Standard + Individual + Telephone Short Counselling
Aubin 2008¹²	Pfizer Inc	Parallel RCT	52	12	Belgium, France, Netherlands, UK, USA	Yes	No	757	379 (51)	93	1. Varenicline Standard + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Austin 2014¹³	Pfizer Grand Award (WS508489)	Parallel RCT	0.14	0.14	Brighton, UK	No	No	80	34 (43)		1. Placebo 2. Placebo 3. Varenicline Low 4. Varenicline Low
Baker 2006¹⁴	National Health and Medical Research Council, Rotary, and Community Health and Tuberculosis Australia	Parallel RCT	52	10	Sydney, Australia and the Newcastle region of NSW, Australia	Yes	No	298	142 (48)		1. NRT Patch (24hrs) High + Individual Long Counselling 2. Usual Care
Baker 2016¹⁵	National Heart, Lung, and Blood Institute, National Cancer Institute	Parallel RCT	52	12	Wisconsin, USA	Yes	No	1086	566 (52)	67	1. NRT Patch (24hrs) + Individual + Telephone Short Counselling 2. Varenicline Standard + Individual + Telephone Short Counselling 3. NRT Combo + Individual + Telephone Short Counselling
Baldassarri 2018¹⁶	Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine and the National Heart, Lung, and Blood Institute	Parallel RCT	24	16	Connecticut, USA	Yes	No	40	21 (53)	65	1. NRT Patch (24hrs) + Individual Long Counselling 2. Electronic Cigarette High + NRT Patch (24hrs) + Individual Long Counselling
Batra 2005¹⁷	Pfizer Consumer Healthcare, Helsingborg, Sweden.	Parallel RCT	56	52	Tübingen, Germany and Zürich, Switzerland	No	No	364	148 (41)		1. NRT Gum High 2. Placebo
Benowitz 2018¹⁸	Pfizer and GlaxoSmithKline	Parallel RCT	28	12	Argentina, Australia, Brazil, Bulgaria, Canada, Chile,	Yes	No	4595	2551 (56)	81	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. Placebo + Individual Short Counselling

					Denmark, Finland, Germany, Mexico, New Zealand, Russian Federation, Slovakia, South Africa, Spain, USA							
Bernstein 2011¹⁹	Grant R21DA017812 from the National Institute on Drug Abuse	Parallel RCT	12	6	New York, USA	Yes	No	338	176 (52)	10	1. Usual Care 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling	
Bernstein 2015²⁰	National Cancer Institute of the National Institutes of Health.	Parallel RCT	52	6	Connecticut, USA	Yes	No	780	407 (52)	39	1. Usual Care 2. NRT Combo + Individual + Telephone Short Counselling	
Bernstein 2016²¹	Grant R01CA141479 from the National Cancer Institute, National Institutes of Health	Parallel RCT	12	4	Connecticut, USA	Yes	No	60	30 (50)	45	1. NRT Combo 2. No Drug Treatment	
Binnie 2007²²	Local NHS Smoking Cessation Services (Smoking Concerns, Glasgow, UK) and the dental school	Parallel RCT	52		Glasgow, UK	Yes	No	118	82 (69)		1. NRT Choice 2. Usual Care	
Bloch 2010²³	Junior Investigator Award from the National Alliance for Research on Schizophrenia and Depression NARSAD (AR) and partially supported by Phillip Morris	Parallel RCT	16	14	Afula, Israel	Yes	No	61	15 (25)		1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling	

Blondal 1999 ²⁴	USA and Phillip Morris International Pharmacia and Upjohn provided the drugs and placebo	Parallel RCT	312	52	Reykjavik, Iceland		No	239	159 (67)		1. NRT Combo Standard + Group Counselling 2. NRT Patch (16hrs) Standard + Group Counselling
Bohadana 2000 ²⁵	Pharmacia & Upjohn Consumer Healthcare, Helsingborg, Sweden	Parallel RCT	52	26	Lorraine, France	Yes	No	400	204 (51)		1. NRT Combo Standard + Individual Short Counselling 2. NRT Inhalator Standard + Individual Short Counselling
Bolliger 2000 ²⁶	Pharmacia and Upjohn Consumer Healthcare, Sweden	Parallel RCT	104	76	Basel and Lausanne, Switzerland	No	No	400	210 (53)		1. NRT Inhalator Standard + Individual Counselling 2. Placebo + Individual Counselling
Bolliger 2011 ²⁷	Pfizer	Parallel RCT	24	12	Brazil, Venezuela, Mexico, Colombia, Costa Rica, South Africa, Egypt, UAE, Lebanon, Saudi Arabia, Lebanon	Yes	No	593	233 (39)	31	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Boyle 1992 ²⁸		Parallel RCT	24	6	Oregon, USA	Yes	Yes	100	3 (3)		1. NRT Gum Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Brandon 2011 ²⁹	Pfizer, Inc. via Investigator Initiated Research Grant #GA3051LP	Parallel RCT	2.2	2.2	Florida, USA	No	No	163	45 (28)	42	1. Varenicline Standard 2. Placebo
Brantmark 1973 ³⁰		Parallel RCT	26	1	Lund, Sweden	Yes	No	92	31 (34)		1. NRT Gum High 2. Placebo
Buchkremer 1988 ³¹	Deutsche Forschungsgemeinschaft	Parallel RCT	52	8	Germany	Yes	No	131	66 (50)		1. NRT Patch (24hrs) Low + Group Counselling 2. Placebo + Group Counselling 3. No Drug Treatment + Group Counselling
Bullen 2010 ³²	Health Research Council and the Heart Foundation of New Zealand	Parallel RCT	24	10	New Zealand	Yes	No	1100	661 (60)		1. NRT Choice + Telephone Counselling 2. NRT Choice + Telephone Counselling
Bullen 2013 ³³	Health Research Council of New Zealand	Parallel RCT	25	13	Auckland, New Zealand	Yes	No	657	405 (62)		1. Electronic Cigarette High + Telephone Short Counselling 2. NRT Patch (24hrs) High + Telephone Short Counselling 3. Placebo + Telephone Short Counselling

Burstein 2006³⁴	Pfizer	Parallel RCT	1.3	1	Orlando, Phoenix, Miami, USA	Not cessation trial	No	24	7 (29)	50	1. Varenicline Low 2. Varenicline Standard 3. Placebo
Caldwell 2014³⁵	Health Research Council of New Zealand. Active Zonic mouth-spray was provided by Niconovum.	Parallel RCT	55	26	Wellington and Christchurch, New Zealand	Yes	No	1423	763 (54)	71	1. NRT Combo High + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Caldwell 2016³⁶	The Health Research Council of New Zealand	Parallel RCT	28	24	Wellington, New Zealand	Yes	No	502	254 (51)		1. NRT Combo High + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Campbell 1983³⁷	Health Education Council and Lundbeck Ltd, who also supplied the chewing gum.	Parallel RCT	52	24	UK		No	1618	599 (37)		1. Usual Care 2. Usual Care 3. Placebo 4. NRT Gum Standard
Campbell 1991³⁸	Pharmacia LEO	Parallel RCT	52	12	UK	Yes	No	212	93 (44)		1. NRT Gum 2. Placebo
Campbell 1996³⁹	Ciba-Geigy Ltd.	Parallel RCT	52	12	UK	Yes	No	234	126 (54)		1. NRT Patch (24hrs) 2. Placebo
Caponnetto 2013⁴⁰	Lega Italiana AntiFumo	Parallel RCT	52	12	Catania, Italy	No	No	300	110 (36)		1. Electronic Cigarette Low 2. Electronic Cigarette Low 3. Placebo
Carpenter 2011⁴¹	National Institute on Drug Abuse	Parallel RCT	26	6	South Carolina, USA	No	No	943	605 (64)	88	1. NRT Lozenge + Telephone Counselling 2. No Drug Treatment + Telephone Counselling
Carpenter 2017⁴²	Support was provided by NIH R21 DA037407 (to M.J. Carpenter), P01 CA200512 (to K.M. Cummings, M.J. Carpenter, and M.L. Goniewicz), UL1 TR001450, and P30 CA138313. M.L. Goniewicz's laboratory is supported via P30 CA016056.	Parallel RCT	16	3	South Carolina, USA	Not necessarily motivated to quit	No	68	41 (60)	54	1. No Drug Treatment 2. Electronic Cigarette High (Three arms collapsed into two based on treatment)

	B.W. Heckman is supported via K12 DA031794 and K23 DA041616. T.L. Wagener's effort is partially supported by the Oklahoma Tobacco Research Center, which is funded by the Oklahoma Tobacco Settlement Endowment Trust										
Carson 2014⁴³	Department of Respiratory Medicine, Queen Elizabeth Hospital, Adelaide, Australia	Parallel RCT	52	12	Adelaide, Australia	Yes	No	392	126 (32)	96	1. Varenicline Standard + Telephone Short Counselling 2. No Drug Treatment + Telephone Short Counselling
Chen 2013⁴⁴	National Health Bureau, Department of Health, Taiwan	Parallel RCT	8	8	Hualien County, Taiwan	Not necessarily motivated to quit	No	184	13 (7)		1. NRT Patch (24hrs) High + Group Short Counselling 2. NRT Patch (24hrs) High + Group Short Counselling
Chengappa 2014⁴⁵	The National Institute of Mental Health (NIMH) of the NIH. Pfizer provided drug/placebo and an investigator-initiated grant	Parallel RCT	24	12	Pittsburgh, Pennsylvania, USA	Yes	No	60	41 (69)	66	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Christen 1984⁴⁶	Merrell Dow Pharmaceuticals, Inc, Cincinnati	Parallel RCT	23	15	Indiana, USA	Yes	No	223	123 (55)		1. NRT Gum Standard 2. Placebo
Cinciripini 1996⁴⁷	DHHS, and by Ciba Geigy Corporation and Marion Merrell Dow	Parallel RCT	56	12	Texas, USA	Yes	No	64	45 (70)	89	1. No Drug Treatment + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Cinciripini 2013⁴⁸	NIDA, NCI; varenicline	Parallel RCT	24	12	Houston, Texas, USA	Yes	No	294	114 (39)	67	1. Varenicline Standard + Individual + Telephone Long Counselling

	supplied by Pfizer										2. Bupropion Standard + Individual + Telephone Long Counselling 3. Placebo + Individual + Telephone Long Counselling
Cinciripini 2018⁴⁹	United States National Institutes of Health (NIH) and by The University of Texas MD Anderson's Cancer Center, funded by the National Cancer Institute (NCI).	Parallel RCT	53	12	Houston, Texas, USA	Yes	No	385	160 (42)	62	1. Varenicline Standard + Bupropion Standard + Individual + Telephone Short Counselling 2. Varenicline Standard + Individual + Telephone Short Counselling 3. Placebo + Individual + Telephone Short Counselling
Cooney 2009⁵⁰	National Institute on Alcohol Abuse and Alcoholism and the Department of Veterans Affairs.	Parallel RCT	52	24	Connecticut, USA	Yes	No	96	28 (29)	90	1. NRT Combo High + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Cosci 2015⁵¹	No funding	Parallel RCT	2	0.07	Florence, Italy	No	No	80	52 (65)		1. NRT Patch (24hrs) Standard 2. Placebo
Covey 2007⁵²	National Institute on Drug Abuse, National Alliance for Research on Schizophrenia and Affective Disorders and the Suzanne C. Murphy Foundation.	Open Label followed by Parallel RCT	48	24	New York, USA	Yes	No	294	131 (45)	70	1. Bupropion Standard + NRT Gum Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Gum Standard + Individual Short Counselling 4. Placebo + Individual Short Counselling
Cox 2012⁵³	federally funded; National Cancer Institute, National Institutes of Health, National Institute for Minority Health and Disparities	Parallel RCT	26	7	Missouri, USA	Yes	No	540	357 (66)	0	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Cravo 2016⁵⁴	Fontem Ventures B.V.	Parallel RCT	12	12	Leeds and Wales, UK	No	No	419	182 (43)		1. Electronic Cigarette Low 2. No Drug Treatment

	Imperial Brands plc is the parent company of Fontem Ventures B.V., the manufacturer of the EVP prototype used in this study										
Croghan 2003⁵⁵	Public Health Service and the National Cancer Institute	Parallel RCT	24	6	USA	Yes	No	1384	803 (58)		1. NRT Patch (16hrs) Standard 2. NRT Nasal Spray Standard 3. NRT Combo Standard
Cummings 2011⁵⁶	New York State Department of Health	Parallel RCT	28	6	New York, USA	Yes	No	2806	1563 (56)		1. NRT Patch (24hrs) + Telephone Short Counselling 2. NRT Patch (24hrs) + Telephone Short Counselling 3. NRT Patch (24hrs) + Telephone Short Counselling
Cummins 2016⁵⁷	National Cancer Institute	Parallel RCT	24	8	California, USA	Yes	No	1270	550 (43)	51	1. NRT Patch (24hrs) High + Telephone Long Counselling 2. No Drug Treatment + Telephone Long Counselling
Dale 1995⁵⁸	Lederle Laboratories, Pearl River, NY	Parallel RCT	52	8	Minnesota, USA	Yes	No	71	39 (55)		1. NRT Patch (24hrs) + Individual + Group Long Counselling 2. NRT Patch (24hrs) Low + Individual + Group Long Counselling 3. NRT Patch (24hrs) High + Individual + Group Long Counselling 4. NRT Patch (24hrs) High + Individual + Group Long Counselling
Dale 2002⁵⁹		Parallel RCT	24	12	Minnesota, USA	Yes	Yes	68	1 (2)	100	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Dale 2007⁶⁰	National Cancer Institute	Parallel RCT	52	12	Minnesota, West Virginia, USA	Yes	Yes	225	0 (0)	98	1. Bupropion Standard 2. Placebo
Dalsgarð 2004⁶¹	GlaxoSmithKline, Denmark	Parallel RCT	26	7	Eastern part of Denmark, Denmark	Yes	No	336	250 (75)		1. Bupropion Standard + Individual Counselling 2. Placebo + Individual Counselling
Daughton 1991⁶²	ALZA Corp, Palo Alto, Calif, Merrell Dow Research Institute, Cincinnati, Ohio.	Parallel RCT	24	4	California and Omaha, USA	Yes	No	158	84 (53)		1. NRT Patch (24hrs) Low + Individual + Group Short Counselling 2. NRT Patch (16hrs) Low + Individual + Group Short Counselling 3. Placebo + Individual + Group Short Counselling
Daughton 1999/TNSG 1991⁶³	Alza Corp.	Two Parallel RCTs	268	12	Indiana, Minnesota, Nebraska, California, Vermont, West	Yes	No	935	564 (60)		1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) Standard + Group Long Counselling 3. NRT Patch (24hrs) Low + Group Long Counselling 4. Placebo + Group Long Counselling

Dautzenberg 2001 ⁶⁴	Novartis Consumer Health	Parallel RCT	26	12	Virginia, Missouri, Oregon, USA	Yes	No	436	227 (52)		1. NRT Lozenge Low 2. Placebo
Davidson 1998 ⁶⁵	Elan Pharmaceutical Research Corporation, Gainesville, Ga	Parallel RCT	24	6	Maryland, Illinois, USA	Yes	No	802	431 (54)	89	1. NRT Patch (24hrs) High 2. Placebo
deJong 2018 ⁶⁶	N/A	Parallel RCT	12.86	4.29	Ede, Deventer, Netherlands	Not necessarily motivated to quit	No	47	19 (40)		1. NRT Patch (24hrs) 2. Placebo
Dogar 2018 ⁶⁷	GRAND 2014, supported by Pfizer	Parallel RCT	25	12	Punjab, Pakistan	Yes	No	510	81 (16)		1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Du 2015 ⁶⁸	GlaxoSmithKline Consumer Healthcare	Parallel RCT	0.14	0.14	New Jersey, USA	No	No	120	72 (60)	74	1. NRT Lozenge Standard 2. NRT Gum Standard (Two out of three arms extracted)
Ebbert 2007 ⁶⁹	National Cancer Institute	Parallel RCT	24	8	Minnesota, USA	Yes	Yes	42		98	1. Placebo + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling
Ebbert 2009 ⁷⁰	National Cancer Institute	Parallel RCT	24	12	Minnesota, USA	Yes	Yes	270	6 (2)	96	1. NRT Lozenge High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2010 ⁷¹	National Cancer Institute	Parallel RCT	24	12	Minnesota and Oregon, USA	Yes	Yes	60	0 (0)	93	1. Placebo + Telephone Short Counselling 2. NRT Lozenge High + Telephone Short Counselling
Ebbert 2011 ⁷²	National Cancer Institute	Parallel RCT	24	12	Minnesota and Wisconsin, USA	Yes	Yes	76	0 (0)	97	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2013 ⁷³	National Institutes of Health	Parallel RCT	24	8	Minnesota, USA	Yes	Yes	52	0 (0)	94	1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2014 ⁷⁴	National Institutes of Health (NIH)	Parallel RCT	52	12	Minnesota, USA	Yes	No	506	239 (47)	93	1. Varenicline Standard + Bupropion Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Ebbert 2015 ⁷⁵	Pfizer	Parallel RCT	52	24	USA, Australia, Canada, Czech Republic, Egypt, Germany, Japan, Mexico, Taiwan, UK	Yes	No	1510	659 (44)	62	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Ebbert 2017 ⁷⁶	Pfizer	Parallel RCT	24	12	Minnesota, USA	Yes	No	93	56 (60)	87	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling

Ehrsam 1991⁷⁷		Parallel RCT	52	9	Basel, Zurich, Switzerland	Yes	No	112			1. NRT Patch (24hrs) 2. Placebo
Eisenberg 2013⁷⁸	Canadian Institutes of Health Research and the Heart and Stroke Foundation of Quebec	Parallel RCT	52	9	Canada, USA, Bangladesh, Iran, Pakistan, India, Tunisia	Yes	No	392	65 (17)		1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Eisenberg 2016⁷⁹	Pfizer	Parallel RCT	24	12	USA and Canada	Yes	No	302	76 (25)		1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ellerbeck 2018⁸⁰	Award CER-1306-0901 from the Patient-Centered Outcomes Research Institute (PCORI), Clinical and Transitional Science Award UL1TR000001 from the NIH–National Center for Advancing Translational Science (NCATS)	Parallel RCT	52	52	Missouri, USA	Not necessarily motivated to quit	No	398	238 (60)	70	1. NRT Combo + Individual + Telephone Short Counselling 2. NRT Combo + Individual + Telephone Short Counselling
Etter 2002⁸¹	Swiss National Science Foundation and the Swiss Federal Office of Public Health	Parallel RCT	264	24	Geneva, Vaud, and Valais, Switzerland	No	No	923	477 (52)		1. NRT Choice Standard 2. Placebo 3. No Drug Treatment
Etter 2009⁸²	Swiss National Science Foundation	Parallel RCT	52	12	Geneva, Vaud, Switzerland	Yes	No	314	132 (42)		1. NRT Gum High 2. NRT Gum High
Evins 2001⁸³	National Association for Research on Schizophrenia and Affective Disorders (NARSAD), Glaxo Wellcome Inc. provided Bupropion HCl sustained	Parallel RCT	24	12	Massachusetts, USA	Yes	No	19	7 (39)	89	1. Bupropion Low + Group Long Counselling 2. Placebo + Group Long Counselling

	release and identical placebo tablets										
Evins 2005⁸⁴	NARSAD and NIDA	Parallel RCT	24	12	Massachusetts, USA	Yes	No	57	14 (27)		1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling
Evins 2007⁸⁵	Massachusetts Department of Mental Health	Parallel RCT	52	12	Massachusetts, USA	Yes	No	51			1. Bupropion Standard + NRT Combo High + Group Long Counselling 2. NRT Combo High + Group Long Counselling
Evins 2014⁸⁶	National Institute on Drug Abuse, Pfizer, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Treatment Strategies for Smoking Cessation in Patients with Schizophrenia to the North Suffolk Mental Health Association	Open treatment (varenicline) followed by Parallel RCT	64	52	Massachusetts, Michigan, New Hampshire, Indiana, Alabama, Minnesota, USA	Yes	No	87	32 (37)	74	1. Varenicline Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Fagerstrom 2010⁸⁷	Pfizer	Parallel RCT	26	12	Norway and Sweden	Yes	Yes	432	46 (11)	100	1. Varenicline Standard 2. Placebo
Fatemi 2013⁸⁸	National Institute on Drug Abuse (grant # R01DA024674-01A1)	Parallel RCT	12	12	Minnesota, USA	Yes	No	24	5 (21)	71	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Fee 1982⁸⁹	LEO Laboratories, Sweden	Parallel RCT	52	5	Tayside, Scotland, UK	Yes	No	352			1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling
Ferry 1992⁹⁰		Parallel RCT	24	12	USA	Yes	No	42	0 (0)		1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling
Ferry 1994⁹¹		Parallel RCT	52	12	California, USA	Yes	No	190			1. Bupropion Standard + Long Counselling 2. Placebo + Long Counselling
Fiore 1994A⁹²	Elan Pharmaceutical Research Corporation	Parallel RCT	24	8	Wisconsin, USA	Yes	No	88	50 (57)		1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling
Fiore 1994B⁹²	Elan Pharmaceutical	Parallel RCT	24	6	Wisconsin, USA	Yes	No	112	76 (68)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling

	I Research Corporation										
Fortmann 1995⁹³	National Heart, Lung, and Blood Institute	Parallel RCT	52		California, USA	Yes	No	1044	438 (42)	80	1. NRT Gum Standard 2. No Drug Treatment 3. NRT Gum Standard 4. No Drug Treatment
Fossati 2007⁹⁴	Mario Negri Institute, Milan, Italy, GlaxoSmithKline	Parallel RCT	52	7	Northern Italy, Italy	Yes	No	593	238 (40)		1. Bupropion Standard + Telephone Counselling 2. Placebo + Telephone Counselling
Foulds 1993⁹⁵	The authors thank the Medical Research Council and Imperial Cancer Research Fund for financial support. Additional support for the Department of Thoracic Medicine at Kings College Hospital, London, England, was provided by Kabi Pharmacia Therapeutics AB	Parallel RCT	12	16	London, UK	Yes	No	248	123 (50)		1. NRT Patch (16 hrs) Standard 2. Placebo
Fouz-Rosón 2017⁹⁶	Fundación Neumosur within the 'Asociación de Neumología y Cirugía Torácica del SUR', Grifols	Parallel RCT	52	8	Seville, Spain	Yes	No	485	196 (41)		1. Varenicline Standard + NRT Gum Standard + Individual + Telephone Long Counselling 2. Varenicline Low + NRT Gum Standard + Individual + Telephone Long Counselling
Fucito 2011⁹⁷	NIH grants P50-AA15632 (SSO), K12-DA000167 (BAT), K05-AA014715 (SSO), and P50-AA012870 (SSO), T32-	Parallel RCT followed by Open-Label Phase	8	8	Connecticut, USA	Yes	No	30	14 (47)	90	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling

	AA015496 (LMF), and the State of Connecticut, Department of Mental Health and Addictions Services										
Gariti 2009⁹⁸	National Institute on Drug Abuse	Parallel RCT	52	9	Pennsylvania, USA	Yes	No	260	148 (57)		1. Bupropion Standard + Individual Short Counselling 2. NRT Patch (24hrs) + Individual Short Counselling 3. Bupropion Standard + Individual Short Counselling 4. NRT Patch (24hrs) + Individual Short Counselling
Garvey 2000⁹⁹	National Institute on Drug Abuse, Department of Veterans Affairs	Parallel RCT	52	23	Massachusetts, USA	Yes	No	608	310 (51)	81	1. Placebo + Individual Short Counselling 2. NRT Gum Standard + Individual Short Counselling 3. NRT Gum High + Individual Short Counselling
Garza 2011¹⁰⁰	Pfizer	Parallel RCT	16	12	California, USA	Yes	No	110	37 (34)	75	1. Varenicline Standard 2. Placebo
George 2002¹⁰¹	National Institute on Drug Abuse, U.S. Department of Veterans Affairs, National Alliance for Research on Schizophrenia and Depression	Parallel RCT	34	9	Connecticut, USA	Yes	No	32	14 (44)	63	1. Bupropion Standard + Group Long Counselling 2. Placebo + Group Long Counselling
George 2008¹⁰²	National Institute on Drug Abuse (NIDA), National Alliance for Research in Schizophrenia and Depression (NARSAD)	Parallel RCT	28	9	Connecticut, USA	Yes	No	59	23 (40)	48	1. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Ginsberg 1992¹⁰³	American Cancer Society and the National Institute on Drug Abuse	Parallel RCT	52	2	California, USA	Yes	No	99	53 (54)		1. NRT Gum Standard 2. NRT Gum Standard + Counselling 3. NRT Gum Standard + Counselling
Glavas 2003A¹⁰⁴		Parallel RCT	260	3	Split-Dalmatia, Croatia	Yes	No	112	74 (66)		1. NRT Patch (24hrs) 2. Placebo

Glavas 2003B ¹⁰⁵		Parallel RCT	30	6	Croatia	Yes	No	160	86 (54)		1. NRT Patch (24hrs) 2. NRT Patch (24hrs) 3. Placebo 4. Placebo
GlaxoSmithKline 2009 ¹⁰⁶	GlaxoSmithKline	Parallel RCT	24	12		Yes	No	723	23 (3)		1. NRT Lozenge Standard 2. Placebo 3. NRT Lozenge High 4. Placebo
GlaxoSmithKline 2011 ¹⁰⁷	GlaxoSmithKline	Parallel RCT	0.14	0.14	Kentucky, USA	No	No	120	72 (60)		1. NRT Lozenge Standard 2. NRT Gum Standard (Two out of three arms extracted)
Glover 2002 ¹⁰⁸	Pharmacia & Upjohn	Parallel RCT	52	24	West Virginia, USA	Yes	No	241	130 (54)		1. NRT Sublingual Tablet + Individual Short Counselling 2. Placebo + Individual Short Counselling
Glover 2002 ¹⁰⁹	GlaxoSmithKline investigator initiated trial	Parallel RCT	12	7	West Virginia, USA	Yes	Yes	70	0 (0)		1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Gonzales 2001 ¹¹⁰	GlaxoWellcome Inc, Research Triangle Park, NC	Parallel RCT	52	12	USA	Yes	No	450	231 (51)	93	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Gonzales 2006 ¹¹¹	Pfizer	Parallel RCT	52	12	USA	Yes	No	1025	471 (46)	79	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Gonzales 2014 ¹¹²	Pfizer	Parallel RCT	52	12	USA, Australia, Belgium, Canada, Czech Republic, France, Germany, UK	Yes	No	498	249 (50)	93	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Gourlay 1995 ¹¹³	Ciba-Geigy Australia, the Anti Cancer Council of Victoria, and the Victorian Health Promotion Foundation	Open Label followed by Parallel RCT	26	12	Melbourne, Australia	Yes	No	629	362 (58)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Graham 2017 ¹¹⁴	National Cancer Institute	Parallel RCT	36	4	USA	Yes	No	5290	3217 (61)	80	1. No Drug Treatment 2. No Drug Treatment 3. NRT Choice 4. NRT Choice
Grant 2007 ¹¹⁵	National Institute on Alcohol Abuse and Alcoholism	Parallel RCT	24	9	Nebraska, USA	Yes	No	58	9 (16)	58	1. NRT Patch (24hrs) High + Group Long Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling
Gray 2015 ¹¹⁶	NIH grants P50DA16511 Component 4 (K.M.G. and M.E.S.),	Parallel RCT	5	4	South Carolina, USA	Yes	No	141	140 (100)	79	1. Nicotine Patch (24hrs) High + Individual Long Counselling 2. Varenicline Standard + Individual Long Counselling

K23DA020482
(M.J.C.) and
UL1RR029882
and
UL1TR000062
(South
Carolina
Clinical and
Translational
Research
Institute)

Haarmann 2016¹¹⁷	Investigator-initiated study funded by Pfizer®	Parallel RCT	33	12	Göttingen, Germany	Yes	No	36	9 (25)	1. Placebo + Group Long Counselling 2. Varenicline Standard + Group Long Counselling
Haggsträm 2006¹¹⁸		Parallel RCT	26	8.57	Porto Alegre, Brazil	Yes	No	156	67 (43)	1. Placebo + Individual + Telephone Short Counselling 2. Bupropion Standard + Individual + Telephone Short Counselling
Hajek 2011¹¹⁹	This study was supported by an investigator-initiated grant from Pfizer (Dr Hajek), who also supplied the study medication. Dr McRobbie's involvement was supported by the United Kingdom Centre for Tobacco Control Studies. Mr Stapleton's involvement was supported by Cancer Research United Kingdom	Parallel RCT followed by Open-Label Phase	16	16	London, UK	Yes	No	101	36 (36)	58 1. Varenicline Standard + Counselling 2. Placebo + Counselling
Hajek 2013¹²⁰	The study was supported by an investigator-initiated grant from Pfizer	Parallel RCT	13	13	London, UK	Yes	No	117	39 (33)	62 1. Varenicline Standard + Counselling 2. Varenicline Standard + NRT Patch (16 hrs) Standard + Counselling

Hajek 2015 ¹²¹	This study was supported by an investigator-initiated grant from Pfizer Inc (Drs Hajek and McRobbie). Pfizer Inc also supplied the study medications	Parallel RCT	12	12	London, UK	Yes	No	200	54 (28)	65	1. Varenicline High + Individual + Telephone Counselling 2. Placebo + Individual + Telephone Counselling
Hajek 2019 ¹²²	National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number, 12/167/135) and by a grant (A16893) from the Cancer Research UK Prevention Trials Unit	Parallel RCT	52	12	London, Leicester, and East Sussex, UK	Yes	No	886	424 (48)		1. Electronic Cigarette High + Individual Counselling 2. NRT Choice + Individual Counselling
Hall 2009 ¹²³	NIH/NIDA	Parallel RCT	104	52	California, USA	Yes	No	402	161 (40)	77	1. Bupropion Standard + NRT Gum + Group Counselling 2. Bupropion Standard + NRT Gum + Individual + Group Long Counselling 3. Bupropion Standard + NRT Gum + Individual + Group Long Counselling 4. Bupropion Standard + NRT Gum + Group Counselling
Hall 2011 ¹²⁴	National Institute on Drug Abuse	Open Label followed by Parallel RCT	104	52	California, USA	Yes	No	407	159 (39)	70	1. No Drug Treatment 2. Placebo 3. Bupropion Standard 4. Placebo + Individual Long Counselling 5. Bupropion Standard + Individual Long Counselling
Hand 2002 ¹²⁵	Author's endowment fund	Parallel RCT	52	3	Cardiff, Wales, UK	Yes	No	245	133 (54)		1. No Drug Treatment + Individual Long Counselling 2. NRT Combo High + Individual Long Counselling
Hanioka 2010 ¹²⁶	Fukuoka Dental College Grant and the Japanese Ministry of Health, Labor and Welfare	Parallel RCT	52	6	Hiroshima, Nagasaki, Japan	Yes	No	56	16 (29)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. No Drug Treatment
Harackiewicz 1988 ¹²⁷	Merrell Dow Pharmaceuticals, Inc., Cincinnati, OH.	Parallel RCT	52	24	New York, USA	Yes	No	197	124 (63)		1. NRT Gum Standard 2. No Drug Treatment 3. No Drug Treatment

Hatsukami 2004¹²⁸	GlaxoSmithKline, Research Triangle Park, North Carolina	Parallel RCT	52	26	USA	Yes	No	609	267 (44)	86	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hawk 2012¹²⁹	2008 Global Research Award for Nicotine Dependence (GRAND) awarded to M.C.M. and by NIDA R21 DA019653 to S.T.T. GRAND is an independent investigator-initiated research program sponsored by Pfizer, Inc	Parallel RCT followed by Open-Label Phase	15	15	New York, USA	Yes	No	60	35 (58)	87	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hays 1999¹³⁰	Elan Pharmaceuticals Research Corp, Gainesville, Ga.	Parallel RCT	24	6	Illinois, California, Minnesota, USA	Yes	No	958	478 (50)	83	1. Placebo 2. NRT Patch (24hrs) High 3. NRT Patch (24hrs) High
Hays 2001¹³¹	Glaxo Wellcome, Inc., Research Triangle Park, North Carolina	Open Label followed by Parallel RCT	104	52	Minnesota, California, Rhode Island, Oregon, Massachusetts, USA	Yes	No	429	219 (51)	97	1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling
Hays 2009¹³²	National Institute on Alcohol Abuse and Alcoholism	Open Label followed by Parallel RCT	76	52	USA	Yes	No	110	24 (22)		1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling
Herrmann 2018¹³³	NIDA R01DA031005, and Dr Herrmann received salary support from NIDA T32DA007294. Dr Haney's research is funded by NIDA. She and Dr Cooper	Parallel RCT	4.43	4.43	New York, USA	No	No	76	11 (14)		1. Placebo 2. Varenicline Standard

	have received partial salary support for an investigator-initiated study from Insys Therapeutics Inc.											
Hertzberg 2001 ¹³⁴	Glaxo Wellcome, Inc., and the National Cancer Institute	Parallel RCT	24	12	North Carolina, USA	Yes	No	15	0 (0)	60	1. Bupropion Standard + Individual Counselling 2. Placebo + Individual Counselling	
Heydari 2012 ¹³⁵	Masih Daneshvari Hospital Research Institute, Tehran	Parallel RCT	52	8	Tehran, Iran	Yes	No	272	112 (41)		1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling	
Hilberink 2011 ¹³⁶		Cluster RCT	52		Nijmegen and Maastricht, The Netherlands	Yes	No	697	356 (51)		1. Usual Care 2. NRT Choice + Individual + Telephone Counselling 3. Bupropion + NRT Choice + Individual + Telephone Counselling	
Hilleman 1994 ¹³⁷		Parallel RCT	24	12	Nebraska, USA	Yes	No	208	114 (55)		1. NRT Patch (24hrs) High + Individual Long Counselling 2. NRT Patch (24hrs) High + Individual Long Counselling	
Hjalmarson 1984 ¹³⁸		Parallel RCT	104	104	Göteborg, Sweden	Yes	No	206	116 (56)		1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling	
Hjalmarson 1994 ¹³⁹	Kabi Pharmacia AB, Helsingborg, Sweden	Parallel RCT	52	52	Göteborg, Sweden	Yes	No	248	142 (57)		1. NRT Nasal Spray Standard + Group Long Counselling 2. Placebo + Group Long Counselling	
Hjalmarson 1997 ¹⁴⁰	Pharmacia & Upjohn, Helsingborg, Sweden	Parallel RCT	52	24	Göteborg, Sweden	Yes	No	247	158 (64)		1. NRT Inhalator Standard + Group Long Counselling 2. Placebo + Group Long Counselling	
Holt 2005 ¹⁴¹	GlaxoSmithKline	Parallel RCT	52	7.4	Wellington and Kapiti, New Zealand	Yes	No	134	96 (72)	0	1. Bupropion Standard + Individual + Telephone Counselling 2. Placebo + Individual + Telephone Counselling	
Hong 2011 ¹⁴²	Stanley Medical Research Institute (grant 06TAF-966), the National Institutes of Health (grants DA027680, MH085646, and MH077852), and the Neurophysiolo	Parallel RCT	8	8	Maryland, USA	Not necessarily motivated to quit	No	69	22 (32)		1. Varenicline Low 2. Placebo (Four arms collapsed into two based on treatment)	

	gy Core of the University of Maryland General Clinical Research Center (grant M01-RR16500)										
Howard-Pitney 1999¹⁴³	National Cancer Institute	Parallel RCT	24	6	California, USA	Yes	Yes	410	4 (1)	95	1. NRT Patch (16hrs) Standard + Telephone Counselling 2. Placebo + Telephone Counselling
Hughes 1989¹⁴⁴	National Institute on Drug Abuse, Washington, DC.	Parallel RCT	52	52	Minnesota, USA	Yes	No	315	176 (56)		1. NRT Gum Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Hughes 1999¹⁴⁵	ALZA and Hoechst Marion Rouse, the National Institute on Drug Abuse	Parallel RCT	52	16	USA and Australia	Yes	No	1039	520 (50)	96	1. Placebo + Individual + Group Long Counselling 2. NRT Patch (24hrs) High + Individual + Group Long Counselling 3. NRT Patch (24hrs) High + Individual + Group Long Counselling 4. NRT Patch (24hrs) High + Individual + Group Long Counselling
Hughes 2003¹⁴⁶	National Institute on Drug Abuse	Parallel RCT	24	12	Vermont and Minnesota, USA	Yes	No	115	37 (32)	93	1. NRT Patch (24hrs) High + Individual + Group Long Counselling 2. Placebo + Individual + Group Long Counselling
Hughes 2010¹⁴⁷	US National Institute on Drug Abuse	Parallel RCT	29	15	South Carolina and New Mexico, USA	Yes	No	750	405 (54)	82	1. NRT Lozenge + Telephone Short Counselling 2. NRT Lozenge + Telephone Short Counselling 3. NRT Lozenge + Telephone Short Counselling
Hughes 2011¹⁴⁸	Pfizer Inc., University of Nebraska Medical Center	Parallel RCT	24	8	Vermont, Nebraska, USA	No	No	220	90 (41)	91	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hurt 1990¹⁴⁹	Elan Pharmaceutical Research Corporation, Gainesville, Georgia, and Athlone, Ireland	Parallel RCT	56	18	Minnesota, USA	Yes	No	70	37 (53)		1. NRT Patch (24hrs) High 2. NRT Patch (24hrs) High
Hurt 1994¹⁵⁰	Study was supported by Lederle Laboratories, NY.	Parallel RCT	52	8	Minnesota, Florida, Arizona, USA	Yes	No	240	127 (53)	100	1. NRT Patch (24hrs) High + Individual + Telephone Counselling 2. Placebo + Individual + Telephone Counselling
Hurt 1997¹⁵¹	Glaxo Wellcome	Parallel RCT	52	7	Minnesota, California, West Virginia, USA	Yes	No	615	336 (55)	96	1. Placebo + Individual Short Counselling 2. Bupropion Low + Individual Short Counselling 3. Bupropion Low + Individual Short Counselling 4. Bupropion Standard + Individual Short Counselling

Hurt 2003 ¹⁵²	National Cancer Institute	Open Label followed by Parallel RCT	60	32	USA	Yes	No	370	211 (57)	87	1. Bupropion Standard 2. Placebo 3. Bupropion Standard 4. Placebo
Hurt 2018 ¹⁵³	National Institutes of Health, Pfizer	Parallel RCT	24	12	Minnesota, USA	Yes	No	33	12 (36)	91	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
ICRF 1994 ¹⁵⁴	Ciba Pharmaceuticals	Parallel RCT	52	12	Oxfordshire, UK	Not necessarily motivated to quit	No	1686	929 (55)		1. NRT Patch (24hrs) High 2. Placebo
Ikonomidis 2017 ¹⁵⁵	Hellenic Cardiac Society	Parallel RCT	52	12	Athens, Greece	Yes		188	86 (45)		1. Varenicline Standard 2. NRT Combo Standard
Jain 2014 ¹⁵⁶	Grants from the National Institute on Drug Abuse (R21 DA026404, R01 DA025078), the National Institute on Drug Abuse and the National Cancer Institute (P50 CA143187), and the National Institute on Drug Abuse, the National Cancer Institute, the National Institute of General Medical Sciences, and the National Human Genome Research Institute (U01 DA020830)	Parallel RCT	12	12	New Delhi, India	Yes	Yes	237	7 (3)		1. Placebo + Individual Counselling 2. Varenicline Standard + Individual Counselling
Jamrozik 1984 ¹⁵⁷	Oxford District Research Committee and Nuffield Dominions Trust	Parallel RCT	24	24	Oxfordshire, UK	Yes	No	200			1. NRT Gum Standard 2. Placebo

Jarvis 1982 ¹⁵⁸	Medical Research Council and Department of Health and Social Security	Parallel RCT	52	52	London, UK	Yes	No	116	64 (55)		1. NRT Gum Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Jennings 2014 ¹⁵⁹	Independent investigator grant from Pfizer Pharmaceuticals to Imperial College London	Parallel RCT	16	12	London, UK, Maarssebroek, Netherlands, Valencia, Spain, and Italy	Yes	No	696	281 (40)		1. Varenicline + Individual + Group Long Counselling 2. Usual Care
Jorenby 1995 ¹⁶⁰	Elan Pharmaceutical Research Corporation	Parallel RCT	26	8	Wisconsin and Minnesota, USA	Yes	No	504	267 (53)	98	1. NRT Patch (24hrs) High + Individual Short, Group Long, or No Counselling 2. NRT Patch (24hrs) High + Individual Short, Group Long, or No Counselling (Six arms collapsed into two arms across treatments)
Jorenby 1999 ¹⁶¹	Glaxo Wellcome	Parallel RCT	52	9	Arizona, California, Nebraska, Wisconsin, USA	Yes	No	893	464 (52)	93	1. Placebo + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling 3. Bupropion Standard + Individual + Telephone Short Counselling 4. Bupropion Standard + NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Jorenby 2006 ¹⁶²	Pfizer Inc	Parallel RCT	52	12	USA	Yes	No	1027	433 (42)	84	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Joseph 1996 ¹⁶³	Hoechst Marion Roussel	Parallel RCT	52	10	Minnesota, Missouri, California, Colorado, North Carolina, Washington, Oregon, Nevada, USA	Yes	No	584	8 (1)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Joseph 2011 ¹⁶⁴	National Cancer Institute/National Institute on Drug Abuse	Parallel RCT	76	52	Minnesota, USA	Yes	No	443	267 (60)	95	1. NRT Choice + Telephone Long Counselling 2. NRT Choice + Telephone Long Counselling
Kalman 2006 ¹⁶⁵	National Institute on Drug Abuse	Parallel RCT	36	12	Massachusetts, USA	Yes	No	130	21 (16)	85	1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Kalman 2011 ¹⁶⁶	National Institute of Drug Abuse, National Institute on Alcohol Abuse and Alcoholism	Parallel RCT	24	8	Massachusetts, USA	Yes	No	143	24 (17)	70	1. NRT Patch (24hrs) High + Individual Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Individual Counselling

Karam-Hage 2011¹⁶⁷	The University of Michigan Medical School Advisory Council on Clinical Research and the University of Michigan's General Clinical Research Center (GCRC) Grant # MO1 RR00042	Parallel RCT	8	8	Michigan, USA	Yes	No	11	6 (55)		1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Killen 1984¹⁶⁸	NIH, Merrell-Dow Pharmaceuticals Inc	Parallel RCT	42	7	California, USA	Yes	No	75	46 (61)		1. NRT Gum Standard 2. No Drug Treatment (Three arms collapsed into two)
Killen 1999¹⁶⁹	National Cancer Institute	Parallel RCT	52	6	California, USA	Yes	No	408	169 (41)	83	1. NRT Patch (16hrs) Standard 2. NRT Patch (16hrs) High
Killen 2006¹⁷⁰	National Cancer Institute	Open Label followed by Parallel RCT	52	25	California, USA	Yes	No	362	167 (46)	86	1. Bupropion Low + Individual Long Counselling 2. Placebo + Individual Long Counselling
Klesges 2015¹⁷¹	National Institutes of Health	Parallel RCT	52	8	Texas, USA	Yes	No	1298	562 (43)	77	1. NRT Choice + Telephone Long Counselling 2. NRT Choice + Telephone Long Counselling
Koegelenberg 2014¹⁷²	Pfizer, New York, New York, and McNeil, Helsingborg, Sweden	Parallel RCT	24	14	Cape Town, Johannesburg, and Durban, South Africa	Yes	No	446			1. Varenicline Standard + NRT Patch (16hrs) Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Kornitzer 1995¹⁷³	Pharmacia Consumer Pharma	Parallel RCT	52	24	Brussels, Belgium	Yes	No	374	146 (39)		1. NRT Combo Standard 2. NRT Patch (16hrs) Standard 3. Placebo
Kralikova 2002¹⁷⁴	McNeil AB, Helsingborg, Sweden, Pharmacia CHC, Helsingborg, Sweden	Parallel RCT	52	36	Prague and Kutna Hora, Czech Republic	Not necessarily motivated to quit	No	314	183 (58)		1. NRT Choice + Individual Short Counselling 2. Placebo + Individual Short Counselling
Kupecz 1996¹⁷⁵		Quasi-experimental Parallel RCT	52	24	Colorado, USA	Yes	No	38	2 (5)		1. NRT Gum Standard + Group Counselling 2. NRT Patch (24hrs) High + Group Counselling
Lee 2013¹⁷⁶	University of Western Ontario Department of Anesthesia and	Parallel RCT	52	6	Ontario, Canada	Yes	No	168	92 (55)		1. Usual Care 2. NRT Patch (24hrs) + Individual Short Counselling

	Perioperative Medicine											
Lee 2018¹⁷⁷	Internal UCSF Department of Anesthesia and Perioperative Care funds (San Francisco, California, United States of America) and the UCSF Resource Allocation Program grant, administered by the Helen Diller Family Comprehensiv e Cancer Center developmental funds from the National Cancer Institute Cancer Center Support Grant (P30 CA 82103-16)	Parallel RCT	24	6	California, USA	Yes	No	30	3 (10)	53	1. NRT Patch (24hrs) + Individual Short Counselling 2. Electronic Cigarette Low + Individual Short Counselling	
Leischow 1996¹⁷⁸	Pharmacia Upjohn, Helsingborg, Sweden	Parallel RCT	52	24	Arizona, USA	Yes	No	222	122 (55)		1. NRT Inhalator Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Lerman 2004¹⁷⁹	National Cancer Institute and the National Institute on Drug Abuse and National Institutes of Health, Abramson Cancer Center and Annenberg Public Policy Center, University of California, San Francisco, Comprehensiv	Parallel RCT	27	8	Washington, DC and Philadelphia, Pennsylvania , USA	Yes	No	350	213 (54)	64	1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Nasal Spray Standard + Group Long Counselling	

	e Cancer Center. Nicotine nasal spray (Nicotrol) was provided by Pharmacia and Upjohn, Helsingborg, Sweden.										
Lerman 2015¹⁸⁰	National Institutes of Health, Canadian Institutes of Health Research, Abramson Cancer Center, Centre for Addiction and Mental Health Foundation, and Pennsylvania Department of Health	Parallel RCT	52	12	Pennsylvania, New York, Texas, USA and Toronto, Canada	Yes	No	1246	543 (44)	55	<ol style="list-style-type: none"> 1. Placebo + Group + Telephone Long Counselling 2. Placebo + Group + Telephone Long Counselling 3. NRT Patch (24hrs) High + Group + Telephone Long Counselling 4. NRT Patch (24hrs) High + Group + Telephone Long Counselling 5. Varenicline Standard + Group + Telephone Long Counselling 6. Varenicline Standard + Group + Telephone Long Counselling
Levin 1994¹⁸¹	Elan Pharmaceuticals, a grant from the National Institute of Drug Abuse (DA 02665), and the Medical Research Service of the Department of Veteran Affairs	Parallel RCT	10	8	North Carolina, USA	Yes	No	62			<ol style="list-style-type: none"> 1. Placebo + Group Counselling 2. NRT Patch (24hrs) High + Group Counselling
Levine 2010¹⁸²	National Institute on Drug Abuse	Parallel RCT	52	26	Pennsylvania, USA	Yes	No	349	349 (100)	86	<ol style="list-style-type: none"> 1. Bupropion Standard + Group Long Counselling 2. Placebo + Group Long Counselling 3. Bupropion Standard + Group Long Counselling 4. Placebo + Group Long Counselling
Lewis 1998¹⁸³	Elan Pharmaceutical Research Corporation, Gainesville, Georgia, and Athlone, Ireland	Parallel RCT	24	6	Wisconsin, USA	Yes	No	185	85 (46)		<ol style="list-style-type: none"> 1. Usual Care 2. Placebo + Telephone Short Counselling 3. NRT Patch (24hrs) High + Telephone Short Counselling

Li 2009 ¹⁸⁴		Parallel RCT	12	4	Shandong, China	Yes	No	69			1. Bupropion Standard 2. Placebo
Lindson-Hawley 2014 ¹⁸⁵	The study was conducted with support from the UK Centre for Tobacco and Alcohol Studies. Paul Aveyard is funded by NIHR Biomedical Research Centre and CLAHRC, Oxford. The study was sponsored by the University of Oxford	Parallel RCT followed by Open-Label Phase	56		London, Nottingham, Birmingham, and Bristol, UK	Yes	No	1792	848 (47)	76	1. No Drug Treatment + Individual Counselling 2. NRT Patch (24hrs) High + Individual Counselling
Litten 2013 ¹⁸⁶	National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Contract HHSN2720090 0005C)	Parallel RCT	16	13	USA	Not cessation trial	No	200	58 (29)	66	1. Varenicline Standard 2. Placebo
Littlewood 2017 ¹⁸⁷	NIDA 1R01DA02507 4-01A2	Parallel RCT	36	12	New Mexico, USA	Yes	No	205	70 (34)	70	1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Llivina 1988 ¹⁸⁸	El Fondo de Investigaciones Sanitarias de la Seguridad Social, la Sociedad Española de Patología Respiratoria, and los Laboratorios PENSA-ESTEVE	Parallel RCT	52	4	Barcelona, Spain	Yes	No	216	71 (33)		1. NRT Gum + Group Counselling 2. Placebo + Group Counselling
Marsh 2005 ¹⁸⁹	GlaxoSmithKline	Parallel RCT	12	12	Ohio, Pennsylvania, Florida, Texas, South Carolina, New York, Alabama, Nevada,	Yes	No	901	475 (53)	84	1. NRT Lozenge High 2. NRT Gum High

					Arizona, Nebraska, New Jersey, North Carolina, Michigan, Louisiana, Tennessee, USA						
Masiero 2018¹⁹⁰	Grant from Fondazione Umberto Veronesi (FUV)	Parallel RCT	12	12	Milan, Italy	Yes	No	210	78 (37)		1. Electronic Cigarette Low + Telephone Short Counselling 2. Placebo + Telephone Short Counselling 3. No Drug Treatment + Telephone Short Counselling
McCarthy 2008¹⁹¹	National Cancer Institute and the National Institute on Drug Abuse	Parallel RCT	52	9	Wisconsin, USA	Yes	No	463	233 (50)	90	1. Placebo + Counselling 2. Bupropion Standard + Counselling (Four arms collapsed into two based on drug treatment)
McClure 2013¹⁹²	Investigator- initiated grant from Pfizer, Inc. and T32- DA07209 from the National Institute on Drug Abuse	Parallel RCT	5	5	Baltimore. USA	Yes	No	104	24 (23)	34	1. Varenicline Standard 2. Placebo
McKee 2009¹⁹³	Grant Nos. 15596, 15496, 15632, 14715 from the National Institute for Alcohol Abuse and Alcoholism; National Institutes of Health Grant Nos. CTSAUL1RR02 4139 DA00436; Department of Mental Health and Addiction Services, State of Connecticut	Parallel RCT	1.1	1	Connecticut, USA	No	No	21	4 (19)	62	1. Varenicline Low 2. Placebo
Mercie 2018¹⁹⁴	The French National	Parallel RCT	48	24	Saint- Etienne,	Yes	No	248	43 (17)		1. Varenicline Standard + Individual Counselling 2. Placebo + Individual Counselling

Institute for Health and Medical Research (INSERM)– French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and Pfizer

Bordeaux, Paris, Le Kremlin Bicetre, Bondy, Bobigny, Suresnes, Fort de France (Martinique), Montpellier, Nice, St Briec, Strasbourg, Caen, Clermont Ferrand, Tourcoing, Vandoeuvre les Nancy, Créteil, Nîmes, France

Merz 1993 ¹⁹⁵		Parallel RCT	12	12	Frankfurt, Germany	Yes	No	160	86 (54)		1. NRT Patch (24hrs) High 2. Placebo
Meszaros 2013 ¹⁹⁶	Brain & Behavior Research Foundation (NARSAD) 2008 Young Investigator Award to Dr Szombathyne Meszaros. Dr Batki has received research funding from NIH/NIAAA (R01 AA013655) and Alkermes	Parallel RCT	12	8	USA	Yes	No	10	3 (30)	50	1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Mitchell 2012 ¹⁹⁷	Supported in part by AA019429-01 and by funds provided by the State of California for medical research on alcohol and	Parallel RCT	16	12	California, USA	No	No	64	26 (41)	69	1. Varenicline Standard + Group Counselling 2. Placebo + Group Counselling

	substance abuse											
Moller 2002 ¹⁹⁸	Grants from the Danish Research Councils, the Danish Ministry of Health, and Director Danielsen's Foundation	Parallel RCT	260	9.43	Copenhagen, Denmark	Not necessarily motivated to quit	No	120	62 (52)		1. NRT + Individual Counselling 2. Usual Care	
Molyneux 2003 ¹⁹⁹	Pharmacia Consumer Healthcare, Helsingborg, Sweden and the Health Education Authority, UK	Parallel RCT	52	6	Nottingham, UK	Yes	No	274	111 (41)	96	1. Usual Care 2. No Drug Treatment + Individual Short Counselling 3. NRT Choice + Individual Short Counselling	
Mori 1992 ²⁰⁰		Parallel RCT	24	12	Tokyo, Japan	No	No	364			1. NRT Gum Standard 2. Placebo	
Mulligan 1990 ²⁰¹	Elan Corporation and the Institute of Biopharmaceutics	Parallel RCT	6	6	Dublin, Ireland	Yes	No	80	42 (53)		1. NRT Patch (24hrs) High + Individual Counselling 2. Placebo + Individual Counselling	
Myles 2004 ²⁰²	The Alfred Hospital Research Trust, GlaxoWellcome, Australia, Australian National Health and Medical Research Council	Parallel RCT	24	7	Australia	Yes	No	47	16 (34)		1. Bupropion Standard 2. Placebo	
Myung 2007 ²⁰³		Parallel RCT	52	6	Goyang, South Korea	Yes	No	118			1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Nahvi 2014 ²⁰⁴	National Center for Research Resources, and the National Institute on Drug Abuse	Parallel RCT	24	12	New York, USA	Yes	No	112	59 (53)	9	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Nakamura 2007 ²⁰⁵	Pfizer Inc.	Parallel RCT	52	12	Japan	Yes	No	619	155 (25)		1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Placebo + Individual Short Counselling	

NCT00365508²₀₆	Fox Chase Cancer Center, National Cancer Institute (NCI)	Parallel RCT	24	12	Washington DC, Florida, Georgia, New Jersey, New York, Pennsylvania, Tennessee, USA	Yes	No	651	365 (56)		1. NRT Patch (24hrs) High + Counselling 2. NRT Lozenge + Counselling
NCT00828113²₀₇	Pfizer	Parallel RCT	78	52	Wisconsin, USA		No	101	43 (43)		1. Varenicline Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
NCT01010477²₀₈	Rutgers, The State University of New Jersey, National Institute on Drug Abuse (NIDA)	Parallel RCT	52	20	New Jersey, USA	Yes	No	52	20 (38)	42	1. NRT Nasal Spray + Counselling 2. Placebo + Counselling
NCT01055886 2009²⁰⁹		Parallel RCT	12	3	North Carolina, USA	Yes	No	65	36 (55)		1. NRT Patch (24hrs) + Short Counselling 1. Placebo + Short Counselling
Niaura 2008²¹⁰	Pfizer, Inc.	Parallel RCT	52	12	USA	Yes	No	320	154 (48)	91	1. Varenicline + Individual Short Counselling 2. Placebo + Individual Short Counselling
Nides 2006²¹¹	Pfizer	Parallel RCT	52	7	USA	Yes	No	638	332 (52)	87	1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Bupropion Standard + Individual Short Counselling 5. Placebo + Individual Short Counselling
Nides 2018²¹²	GlaxoSmithKline/McNeil AB	Parallel RCT	26	12	USA	Yes	No	1198	651 (54)	60	1. NRT Mouth Spray Standard 2. Placebo
Nides 2018A²¹³	GlaxoSmithKline Consumer Healthcare, Warren, NJ	Parallel RCT	0.86	0.14	California, USA	Not necessarily motivated to quit	No	187	84 (45)	35	1. NRT Lozenge High 2. Placebo 3. NRT Lozenge Low 4. Placebo
Nides 2018B²¹³	GlaxoSmithKline Consumer Healthcare, Warren, NJ	Parallel RCT	0.86	0.14	California, USA	Not necessarily motivated to quit	No	323	149 (46)	40	1. NRT Lozenge High 2. Placebo
Olson 2009²¹⁴		Parallel RCT	0.71	0.14	New York, USA	No	No	28	22 (79)		1. Placebo 2. NRT Patch (16hrs) Low 3. NRT Patch (16hrs) Low 4. NRT Patch (16hrs) Standard
O'Malley 2017²¹⁵	Grants R01AA020388, R01AA020389, P50AA012870, T32DA019426, K23AA020000, and K05AA014715 from the National Institutes of Health and by	Parallel RCT	52	18	Connecticut and New York, USA	Not necessarily motivated to quit	No	131	39 (30)	38	1. Varenicline Standard 2. Placebo

the State of
Connecticut
Department of
Mental Health
and Addiction
Services

Oncken 2006²¹⁶	Pfizer Inc	Parallel RCT	52	12	USA	Yes	No	518	262 (51)	80	1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Varenicline Standard + Individual Short Counselling 5. Placebo + Individual Short Counselling
Oncken 2007²¹⁷	The Patrick and Catherine Weldon Donaghue Foundation, The University of Connecticut Center on Aging, University of Connecticut General Clinical Research Center and the National Institute for Health	Parallel RCT	68	16	Connecticut, USA	Yes	No	152	152 (100)	89	1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling
Pack 2008²¹⁸	This research was supported by the National Cancer Institute Grant P50CA084724 and the National Institute on Drug Abuse Grant # P50DA19706	Parallel RCT	52	8	Wisconsin, USA	Yes	No	408	229 (56)	71	1. NRT Lozenge + Telephone or No Counselling 2. NRT Gum + Telephone or No Counselling (Four arms collapsed to two across drugs)
Paoletti 1996²¹⁹	Pharmacia	Parallel RCT	52	18	Pisa, Tuscany, Italy	Yes	No	297	119 (40)		1. Placebo 2. NRT Patch (16hrs) Standard 3. NRT Patch (16hrs) Standard 4. NRT Patch (16hrs) High
Pei 2014²²⁰		Parallel RCT		4	Wuhan, China	Yes	No	120	0 (0)		1. NRT Combo + Individual Counselling 2. Usual Care
Perng 1998²²¹	Orient Europharma Company Limited, Taipei, Taiwan	Parallel RCT	52	6	Taiwan	Yes	No	62	4 (6)	0	1. NRT Patch (24hrs) High 2. Placebo

Piper 2009 ²²²	University of Wisconsin–Madison, the National Institute on Drug Abuse and the General Clinical Research Centers Program of the National Center for Research Resources	Parallel RCT	26	12	Wisconsin, USA	Yes	No	1504	876 (58)	84	1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Lozenge + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling 5. Bupropion Standard + NRT Lozenge + Individual Short Counselling 6. NRT Combo High + Individual Short Counselling
Piper 2018 ²²³	National Cancer Institute [grant P01CA180945], National Institute on Alcohol Abuse and Alcoholism [grant R01AA022931], National Institute on Drug Abuse [grants R01DA040480 and P50DA039838], and National Institute of Diabetes and Digestive and Kidney Disease [grant R01DK097364]	Parallel RCT	55	29	Wisconsin, USA	Yes	No	623	357 (57)	69	1. NRT Patch (24hrs) + Individual Short Counselling 2. NRT Combo + Individual + Telephone Short Counselling
Planer 2011 ²²⁴	GlaxoSmithKline	Parallel RCT	52	8	Jerusalem, Israel	Yes	No	151	30 (20)		1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Plebani 2013 ²²⁵	NIH Grants P60-DA-005186 and P50-DA-12756	Parallel RCT	13	12	Philadelphia, USA	No	No	40	6 (15)	58	1. Varenicline Standard 2. Placebo
Poling 2010 ²²⁶	New England Veterans Administration MIRECC, and by grants R01DA021264	Parallel RCT	12	11	Connecticut, USA	No	No	31	6 (19)	61	1. Varenicline Standard 2. Placebo

	(Dr. Poling) and R01DA014537 (Dr. Sofuoglu) from the National Institute on Drug Abuse, Bethesda, MD										
Ponciano-Rodriguez 2014²²⁷	Grant from the Medica Sur Clinical & Foundation	Parallel RCT	10	9	Mexico City, Mexico	Yes	No	48	25 (52)		1. No Drug Treatment + Counselling 2. NRT Combo + Counselling 3. Varenicline Standard + Counselling
Puska 1979²²⁸		Parallel RCT	24	3	North Karelia (Eastern Finland), Finland	Yes	No	229	39 (17)		1. NRT Gum High + Group Long Counselling 2. Placebo + Group Long Counselling
Puska 1995²²⁹		Parallel RCT	52	26	North Karelia (Eastern Finland), Finland	Yes	No	300	137 (46)		1. NRT Combo Standard 2. NRT Gum Standard
Ramon 2014²³⁰	Pfizer	Parallel RCT	24	12	Barcelona, Spain	Yes	No	341	144 (42)		1. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Ratner 2004²³¹	National Cancer Institute of Canada, Canadian Cancer Society, Canadian Institutes of Health Research, Social Sciences and Humanities Research Council of Canada and the Michael Smith Foundation for Health Research	Parallel RCT	62	16	British Columbia, Canada	Yes	No	237	123 (52)		1. Usual Care 2. NRT Gum + Individual + Telephone Short Counselling
Ray 2014²³²	This research was supported grants from the California Tobacco Related Disease Research	Parallel RCT	1.29	1.29	California, USA	No	No	130	42 (32)	23	1. Varenicline Standard 2. Placebo (Two out of four arms extracted)

Program (TRDRP 18KT-0020) and from the National Institute on Drug Abuse (DA030898) to LAR. Support for this study was also provided by a grant from the UCLA Clinical and Translational Science Institute (CTSI), grants UL1RR033176 and UL1TR000124. KEC was supported by the UCLA Training Program in Translational Neuroscience of Drug Abuse (T32 DA024635)

Reid 2003 ²³³		Parallel RCT	52	8	Ontario, Canada	Yes	No	254	49 (19)	1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Low + Individual Short Counselling
Rennard 1994 ²³⁴	Research grant from Alza Corp, Palo Alto, Calif	Parallel RCT	5	5	California, Nebraska, Colorado, Missouri, USA	Yes	No	156	32 (21)	1. NRT Patch (24hrs) + Group Counselling 2. Placebo + Group Counselling
Rennard 2006 ²³⁵		Parallel RCT	64	52	Arizona, West Virginia, Nebraska, USA	No	No	429	237 (55)	1. NRT Inhalator Standard 2. Placebo
Rennard 2012 ²³⁶	Pfizer Inc.	Parallel RCT	24	12	Argentina, Brazil, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Mexico, Republic of	Yes	No	659	264 (40)	68 1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling

					Korea, Taiwan, UK, USA						
Richmond 1994 ²³⁷	Marion Merrell Dow	Parallel RCT	520	10	Sydney, Australia	Yes	No	315	164 (52)		1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling
Rigotti 2006 ²³⁸	NHLBI, the NIH General Clinical Research Centers Program and GlaxoSmithKline, Inc (GSK)	Parallel RCT	52	12	Massachusetts, USA	Yes	No	254	79 (31)	94	1. Bupropion Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Rigotti 2010 ²³⁹	Pfizer Inc.	Parallel RCT	52	12	Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Mexico, Netherlands, Republic of Korea, Taiwan, UK, USA	Yes	No	714	152 (21)	81	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Rodriguez-Artalejo 2003 ²⁴⁰	Universidad del País Vasco	Parallel RCT	52	12	Bilbao, Spain	Yes	No	218	30 (14)		1. Usual Care 2. NRT Patch (24hrs) + Individual Short Counselling
Rohsenow 2017 ²⁴¹	National Institute on Drug Abuse and the Department of Veterans Affairs	Parallel RCT	24	13	Rhode Island, USA	Not necessarily motivated to quit	No	137	64 (47)	83	1. Varenicline Standard + Individual Long Counselling 2. NRT Patch (24hrs) High + Individual Long Counselling
Rose 1990 ²⁴²	Ciba-Geigy, Inc., and the Medical Research Service of the Veterans Administration	Parallel RCT	3	3	California, USA	Yes	No	65			1. NRT Patch (24hrs) High + Group Counselling 2. Placebo + Group Counselling
Rose 2009 ²⁴³	Grant to Duke University from Philip Morris, USA	Parallel RCT	24	12	North Carolina, USA	Yes	No	379	217 (57)	81	1. NRT Patch (24hrs) High 2. NRT Patch (24hrs) High (Two out of four arms extracted)
Rose 2013 ²⁴⁴	Philip Morris USA	Open Label followed by Parallel RCT	26	15	North Carolina, USA	Yes	No	570	253 (46)	63	1. NRT Patch (24hrs) High + Individual Short Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Individual Short Counselling

											3. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling 5. NRT Patch (24hrs) High + Individual Short Counselling 6. Bupropion Standard + NRT Patch (24hrs) High + Individual Short Counselling 7. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling
Rose 2014 ²⁴⁵	Grant 1P50 DA027840 from the National Institute on Drug Abuse and a grant from Philip Morris, USA	Open Label followed by Parallel RCT	24	12	North Carolina, USA	Yes	No	222	120 (54)	62	1. Varenicline Standard + Individual Short Counselling 2. Varenicline Standard + Bupropion Standard + Individual Short Counselling
Rose 2017 ²⁴⁶	Grant 1P50 DA027840 from the National Institute on Drug Abuse and a grant from Philip Morris, USA	Open Label followed by Parallel RCT	13	12	North Carolina, USA	Yes	No	174	0 (0)	71	1. Varenicline Standard + Bupropion Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Rovina 2009 ²⁴⁷		Parallel RCT	71	19	Athens, Greece	Yes	No	205	82 (40)	100	1. Bupropion Low + Individual Short Counselling 2. Bupropion Low + Group Long Counselling 3. Bupropion Low + Group Long Counselling 4. No Drug Treatment + Group Long Counselling
Rungruanghiranya 2008 ²⁴⁸	Thai Health Promotion Foundation, and Srinakharinwirot University	Parallel RCT	12	12	Nakornnayok, Nonthaburi, Thailand	Yes	No	43	1 (2)		1. NRT Gum + Individual Short Counselling 2. Placebo + Individual Short Counselling
Russell 1983 ²⁴⁹	Medical Research Council and the AB Leo Research Foundation, Sweden	Parallel RCT	52		South London and Kent, UK	Yes	No	2106	1200 (57)		1. No Drug Treatment 2. No Drug Treatment 3. NRT Gum Standard
Rutgers 2011 ²⁵⁰	Rutgers, The State University of New Jersey; Pfizer	Parallel RCT	24	4	New Jersey, USA	No	No	63	31 (49)		1. Varenicline Standard + Counselling 2. Placebo + Counselling
Sachs 1993 ²⁵¹	National Institute on Drug Abuse and by Kabi Pharmacia AB	Parallel RCT	52	18	California, USA	Yes	No	220	130 (59)		1. NRT Patch (16hrs) Standard 2. Placebo

	and Parke-Davis										
SadrAzodi 2009²⁵²	Swedish National Institute of Public Health and the Regional county council (Stockholm Lans Landsting), Olle Engkvist Byggmastare Foundation	Parallel RCT	60	8	Stockholm, Sweden	Yes	No	117	48 (47)		1. NRT Choice + Individual + Telephone Counselling 2. Usual Care
Schacht 2014²⁵³	Grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), including the Charleston Alcohol Research Center (P50 AA010761). Drs. Schacht and Anton are supported by K99 AA021419 and K05 AA017435, respectively	Parallel RCT	2	2	South Carolina, USA	No	No	40	17 (43)		1. Varenicline Standard 2. Placebo
Schmitz 2007²⁵⁴	National Institute on Drug Abuse	Parallel RCT	52	7	Texas, USA	Yes	No	154	154 (100)	70	1. Placebo + Group Long Counselling 2. Placebo + Group Long Counselling 3. Bupropion Standard + Group Long Counselling 4. Bupropion Standard + Group Long Counselling
Schneider 1983A²⁵⁵	National Institute on Drug Abuse and the Medical Research Service of the Veterans Administration	Parallel RCT	52		California, USA	Yes	No	60	36 (60)		1. NRT Gum Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Schneider 1995²⁵⁶	VA Merit Review and Pharmacia (Sweden)	Parallel RCT	52	24	California, USA	Yes	No	255	114 (45)		1. NRT Nasal Spray Standard 2. Placebo
Schneider 1996²⁵⁷	VA Merit Review and by	Parallel RCT	52	24	California, USA	Yes	No	223	83 (37)		1. NRT Inhalator Standard 2. Placebo

	Pharmacia & Upjohn, Sweden											
Schnoll 2010A ²⁵⁸	National Cancer Institute and the National Institute on Drug Abuse	Parallel RCT	52	24	Pennsylvania , USA	Yes	No	575	257 (45)	85	1. NRT Patch (24hrs) High + Counselling 2. NRT Patch (24hrs) High + Counselling	
Schnoll 2010B ²⁵⁹	American Cancer Society and National Institutes of Health	Parallel RCT	24	12	Pennsylvania , New York, Washington DC, Louisiana, Georgia, Tennessee, Florida, New Jersey, USA	Yes	No	651	365 (57)	63	1. NRT Patch (24hrs) High + Individual Long Counselling 2. NRT Lozenge + Individual Long Counselling	
Schnoll 2013 ²⁶⁰	Grants from the National Institute on Drug Abuse (NIDA ; R21 DA026889 , R01 DA025078 , P30 DA12393), by a grant from the NIDA and the National Cancer Institute (NCI ; P50 CA143187), and by a grant from the NIDA , the NCI , the National Institute of General Medical Sciences , and the National Human Genome Research Institute (U01 DA020830)	Parallel RCT	9	8	Pennsylvania , USA	Yes	No	87	45 (52)	69	1. NRT Patch (24hrs) High + Individual + Telephone Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Counselling	
Schnoll 2015 ²⁶¹	National Institute on Drug Abuse and the National Cancer Institute	Parallel RCT	52	52	Pennsylvania and Illinois, USA	Yes	No	525	266 (51)	48	1. NRT Patch (24hrs) High + Individual + Telephone Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Counselling 3. NRT Patch (24hrs) High + Individual + Telephone Counselling	

Schnoll 2019 ²⁶²	NIH, Grant/Award Numbers: K24 DA045244 and R01 CA165001	Open Label followed by Parallel RCT	52	24	Pennsylvania, USA	Yes	No	207	105 (50)	70	1. Varenicline Standard + Individual + Telephone Counselling 2. Varenicline Standard + Individual + Telephone Counselling
Schuermans 2004 ²⁶³	Grant from the Swiss Science Foundation (MMS)	Parallel RCT followed by Open-Label Phase	28	14	Cape metropolis, South Africa	Yes	No	200	88 (44)	87	1. NRT Patch (16hrs) + Individual Short Counselling 2. NRT Patch (16hrs) + Individual Short Counselling
Selby 2003 ²⁶⁴	GlaxoSmithKline	Parallel RCT	52	12	Canada	Yes	No	284	146 (51)	98	1. Bupropion Standard + Counselling 2. Placebo + Counselling
SelmaBozkurt Zincir 2013 ²⁶⁵		Parallel RCT	28	12	Istanbul, Turkey	Yes	No	251			1. Bupropion Standard 2. Varenicline Standard 3. NRT Choice
Severson 2015 ²⁶⁶	National Cancer Institute of the National Institutes of Health	Parallel RCT	24	12	Oregon, USA	Yes	Yes	1067	26 (2)	96	1. No Drug Treatment + Telephone Long Counselling 2. NRT Lozenge High 3. NRT Lozenge High + Telephone Long Counselling
Sharma 2018 ²⁶⁷	EU-FP7 and ICMR	Parallel RCT	24	6	National Capital Region of Delhi and Andhra Pradesh, India	Yes	No	800	2 (0.3)		1. NRT Gum + Individual Short Counselling 2. No Drug Treatment + Individual Short Counselling
Sheng 2013 ²⁶⁸	Zhejiang Jinxin Pharmaceutical Co, Ltd	Parallel RCT	12	9	Beijing, China	Yes	No	257	14 (5)		1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling
Sherman 2008 ²⁶⁹	California Tobacco-Related Disease Research Program and by the VA Health Services Research and Development Center of Excellence for the Study of Health Care Provider Behavior	Parallel Quasi-RCT	26	8	California, USA	Yes	No	178			1. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling 2. Bupropion Standard + Group Long Counselling
Shiffman 2002 ²⁷⁰	GlaxoSmithKline Consumer Healthcare, Parsippany, NJ	Parallel RCT	52	24	Bristol, London, Glasgow, Coventry, UK and Minnesota, Texas,	Yes	No	1818	1031 (57)	94	1. NRT Lozenge Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling 3. NRT Lozenge High + Individual Short Counselling 4. Placebo + Individual Short Counselling

					Oklahoma, Utah, New Jersey, Kentucky, New York, North Carolina, USA						
Shiffman 2006 ²⁷¹	Grant DA06084 to Saul Shiffman from the National Institute on Drug Abuse	Parallel RCT	8	6	Pennsylvania, USA	Yes	No	324	166 (51)	85	1. NRT Patch (24hrs) High + Group Counselling 2. Placebo + Group Counselling
Shiffman 2009 ²⁷²	SmithKline Beecham Consumer Healthcare, now GlaxoSmithKline Consumer Healthcare (GSKCH)	Parallel RCT	24	24	Texas, Washington, New Jersey, Oklahoma, Arizona, Oregon, Minnesota, Arkansas, New York, Utah, Florida, Illinois, California, Nebraska, Massachusetts, USA	Yes	No	3297	1878 (57)	87	1. Placebo 2. NRT Gum Standard 3. Placebo 4. NRT Gum High
Shim 2012 ²⁷³	Grant from the Stanley Medical Research Institute (07TGS-1051)	Parallel RCT	8	8	Korea	Not cessation trial	No	120	34 (28)	0	1. Varenicline Standard 2. Placebo
Shoptaw 2008 ²⁷⁴		Parallel RCT	14	12	California, USA	Not necessarily motivated to quit	No	73	26 (36)	56	1. Bupropion Standard + Individual Counselling 2. Placebo + Individual Counselling
Siddiqi 2013 ²⁷⁵	International Development Research Centre	Cluster RCT	25	7	Jhang and Sargodha, Pakistan	Yes	No	1955	90 (5)	0	1. Bupropion Low + Individual Long Counselling 2. No Drug Treatment + Individual Long Counselling 3. Usual Care
Simon 1997 ²⁷⁶	California Tobacco-Related Disease Research Program, Oakland	Parallel RCT	52	12	California, USA	Yes	No	324		69	1. NRT Choice + Individual + Telephone Long Counselling 2. No Drug Treatment + Individual Short Counselling
Simon 2004 ²⁷⁷	California Tobacco-	Parallel RCT	52	8	California, USA	Yes	No	244	34 (14)	69	1. Bupropion Standard + NRT Patch (24hrs) High + Individual + Telephone Long Counselling

	Related Disease Research Program, Oakland, Calif.										2. NRT Patch (24hrs) High + Individual + Telephone Long Counselling
Simon 2009²⁷⁸	California Tobacco-Related Disease Research Program	Parallel RCT	24	7	California, USA	Yes	No	85	3 (4)	74	1. Bupropion Standard + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling
Singh 2010²⁷⁹	Nil	Parallel RCT	16	7	Delhi, India	Yes	No	30	1 (3)		1. Bupropion Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Smith 2009²⁸⁰	National Institutes of Health from the National Institute on Drug Abuse and the National Cancer Institute, UW-Madison	Parallel RCT	24	12	Wisconsin, USA	Yes	No	1346	753 (56)	87	1. Bupropion Standard + Telephone Counselling 2. NRT Lozenge + Telephone Counselling 3. NRT Patch (24hrs) High + Telephone Counselling 4. Bupropion Standard + NRT Lozenge + Telephone Counselling 5. NRT Combo High + Telephone Counselling
Smith 2016²⁸¹	Grant from Stanley Medical Research Foundation (www.stanelyresearch.org)	Parallel RCT	12	12	New York, USA, Tel Aviv, Israel, Beijing, China	Not necessarily motivated to quit	No	91		31	1. Placebo + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
SMK20001²⁸²	GlaxoSmithKline	Parallel RCT	52	7	USA	Yes	No	286	138 (48)	93	1. Placebo 2. Bupropion Standard
Sonderskov 1997²⁸³	Ciba-Geigy	Parallel RCT	26	12	Aarhus and Copenhagen, Denmark	Yes	No	522	330 (63)		1. NRT Patch (24hrs) 2. Placebo (Four arms collapsed into two across treatments)
Sorensen 2003²⁸⁴	Grants from The Danish Research Council (no. 9801273), The Danish Health Insurance Fund, and Bispebjerg Hospital	Parallel RCT	7.29	3	Copenhagen, Denmark	Yes	No	60	20 (33)		1. NRT Choice + Individual + Telephone Counselling 2. No Drug Treatment
Southern Illinois University Carbondale 2005²⁸⁵	Southern Illinois University Carbondale; National Institute on	Parallel RCT	12	8.86	Illinois, USA	Yes	No	127	58 (46)		1. Bupropion Standard 2. NRT Patch (24hrs) High 3. Placebo 4. Waitlist

Study	Year	Design	Age (M)	Age (F)	Location	Motivated to quit	Quit	N	Quit (n)	Quit (%)	Interventions
Stanford University	2011 ²⁸⁶	Parallel RCT	4.43	4.43	California, USA	Not necessarily motivated to quit	No	17	6 (35)	35	1. Placebo + Counselling 2. Varenicline Low + Counselling
Stapleton	1995 ²⁸⁷	Parallel RCT	52	18	15 English counties, including London, UK	Yes	No	1200	686 (57)	57	1. NRT Patch (16hrs) + Individual Short Counselling 2. Placebo + Individual Short Counselling
Stapleton	2011 ²⁸⁸	Parallel RCT	12	12	England, UK	Yes	No	761	436 (57)	57	1. NRT Nasal Spray Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Stapleton	2013 ²⁸⁹	Parallel RCT	24	12	London, Essex, UK	Yes	No	1071	570 (53)	53	79 1. NRT Choice + Group Long Counselling 2. Bupropion Standard + Group Long Counselling 3. Bupropion Standard + NRT Choice + Group Long Counselling
Stein	2013 ²⁹⁰	Parallel RCT	24	24	New England, USA	Yes	No	315	159 (50)	50	79 1. NRT Combo High + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Steinberg	2009 ²⁹¹	Parallel RCT	26	26	New Jersey, USA	Yes	No	127	82 (65)	65	61 1. Bupropion Low + NRT Combo High 2. NRT Patch (24hrs) High
Steinberg	2011 ²⁹²	Parallel RCT	24	12	Moderate-sized urban center, USA	Yes	No	79	32 (41)	41	72 1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Steinberg	2018 ²⁹³	Parallel RCT	24	4	New Jersey, USA	No	No	64	29 (45)	45	47 1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Sutherland	1992 ²⁹⁴	Parallel RCT	182	12	London, UK	Yes	No	227	146 (64)	64	1. NRT Nasal Spray Standard + Group Long Counselling 2. Placebo + Group Long Counselling

	Cancer Research Fund											
Swan 2003 ²⁹⁵	National Cancer Institute, Bethesda, Md	Parallel RCT	52	8	Washington, USA	Yes	No	1524	875 (57)	90	1. Bupropion Low + Telephone Counselling 2. Bupropion Standard + Telephone Counselling (Four arms collapsed into two across treatments)	
Tashkin 2001 ²⁹⁶	Glaxo Wellcome Inc, USA	Parallel RCT	26	12	USA	Yes	No	411	185 (45)	95	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling	
Tashkin 2011 ²⁹⁷	Pfizer Inc	Parallel RCT	52	12	USA, Spain, France, Italy	Yes	No	504	188 (38)	83	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling	
Thomsen 2010 ²⁹⁸	The Lundbeck Foundation, Doctor Fritz Karner and wife Edith Karner's Foundation, Aase og Einar Danielsen's Foundation, The Research Council at Herlev University Hospital, Civil Engineer Bent Bøgh and Wife Inge Bøgh's Foundation, and The Tryg Foundation	Parallel RCT	52	2	Denmark	Yes	No	130	130 (100)		1. NRT Choice + Individual Long Counselling 2. Usual Care	
Thorsteinsson 2001 ²⁹⁹	Supported in part by a grant from NIH to UCSD MHCRC MH30914, and a grant from Tobacco Related Disease Research Program #4RT-0301 (JCG)	Parallel RCT	4.14	3	California, USA	Yes	No	38	18 (47)	84	1. Placebo + Group + Telephone Counselling 2. NRT Patch (24hrs) High + Group + Telephone Counselling	
Tidey 2011 ³⁰⁰		Parallel RCT	3.14	3	Rhode Island, USA	Yes	No	57	15 (26)	68	1. Bupropion Standard 2. Placebo (Four arms collapsed into two across treatments).	
Tonnesen 1988 ³⁰¹	Danish National Tuberculosis Foundation	Parallel RCT	104	16	Copenhagen, Denmark	Yes	No	173	98 (57)		1. NRT Gum High + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling 3. NRT Gum Standard + Group Long Counselling 4. Placebo + Group Long Counselling	
Tonnesen 1988 ³⁰²	H. Lundbeck A/S, Denmark	Parallel RCT	92	12	Copenhagen, Denmark	Yes	No	172	95 (55)		1. NRT Gum Standard + Group Long Counselling 2. NRT Gum High + Group Long Counselling	

	and the Danish National Tuberculosis Society									3. No Drug Treatment
Tonnesen 1991³⁰³	Kabi Pharmacia Therapeutics	Parallel RCT	156	16	Copenhagen, Denmark	Yes	No	289	202 (70)	1. NRT Patch (16hrs) Standard 2. Placebo
Tonnesen 1993³⁰⁴	Kabi Pharmacia Therapeutics, Helsingborg, Sweden	Parallel RCT	52	24	Copenhagen, Denmark	Yes	No	286	172 (60)	1. NRT Inhalator Standard 2. Placebo
Tonnesen 1999³⁰⁵	European Respiratory Society and Pharmacia & Upjohn, Sweden	Parallel RCT	52	26	Austria, Belgium, Denmark, England, Finland, France, Germany, Greece, Ireland, Italy, Norway, Poland, Portugal, Spain, Sweden, Switzerland, The Netherlands	Yes	No	3575	1716 (48)	1. NRT Patch (16hrs) High 2. NRT Patch (16hrs) Standard 3. Placebo (Five arms collapsed into three based on dosage)
Tonnesen 2000³⁰⁶	Pharmacia & Upjohn, Helsingborg, Sweden and the Danish Lung Foundation	Parallel RCT	52	36	Hellerup, Denmark	Yes	No	446	232 (52)	1. NRT Patch (16hrs) Low + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Short Counselling 3. NRT Inhalator Standard + Individual Short Counselling 4. NRT Combo Standard + Individual Short Counselling
Tonnesen 2003³⁰⁷	GlaxoSmithKline	Parallel RCT	52	7	Norway, Sweden, Denmark, the Netherlands, France, South Africa, Australia and New Zealand	Yes	No	710	362 (51)	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Tonnesen 2006³⁰⁸	The Danish Medical Research Council and Pfizer Consumer Healthcare, Sweden	Parallel RCT	52	12	Hellerup, Denmark	Yes	No	370	193 (52)	1. Placebo + Individual + Telephone Long Counselling 2. NRT Sublingual Tablet + Individual + Telephone Long Counselling (Four arms collapsed into two based on dosage)

Tønnesen 2012 ³⁰⁹	McNeil AB, Sweden	Parallel RCT	52	24	Copenhagen, Mannheim, Tübingen, Denmark and Germany	Yes	No	479	210 (44)		1. NRT Mouth Spray Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tonstad 2003 ³¹⁰	GlaxoSmithKline	Parallel RCT	52	7	Australia, Austria, Germany, Greece, Hungary, Netherlands, New Zealand, Norway, Switzerland, UK	Yes	No	629	145 (23)	99	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Tonstad 2006 ³¹¹	Pfizer Inc	Parallel RCT	52	12	USA, Canada, Czech Republic, Denmark, Norway, Sweden, UK	Yes	No	1210	614 (51)	97	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tsai 2007 ³¹²	Pfizer Inc	Parallel RCT	24	12	Korea, Taiwan	Yes	No	250	28 (11)	0	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tseng 2016 ³¹³	National Center for Advancing Translational Sciences at the National Institutes of Health (grant number UL1TR000038)	Parallel RCT	12	3	New York, USA	Not necessarily motivated to quit	No	100	32 (32)	30	1. Electronic Cigarette + Telephone Long Counselling 2. Placebo + Telephone Long Counselling
Tsukahara 2010 ³¹⁴	Ministry of Education, Science and Culture of Japan, Central Research Institute of Fukuoka University and FU-Global program	Parallel RCT	24	12	Nanakuma, Japan	Yes	No	32	5 (16)	0	1. Varenicline Standard + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Tuisku 2016 ³¹⁵	Ministry of Social Affairs and Health, governmental subsidy, Finnish Research Foundation of	Parallel RCT	26	12	Rovaniemi, Kemi and Tornio, municipality of Sodankylä, Finland	Yes	No	291	146 (50)		1. Placebo + Individual Long Counselling 2. NRT Patch (16hrs) Low + Individual Long Counselling 3. NRT Patch (16hrs) Standard + Individual Long Counselling 4. Varenicline Standard + Individual Long Counselling

the Pulmonary
Diseases and
The Finnish
Medical
Society
Duodecim

Tulloch 2016 ³¹⁶	Heart and Stroke Foundation of Ontario	Parallel RCT	52	24	Ontario, Canada	Yes	No	737	342 (47)	92	1. NRT Patch (24hrs) + Individual Short Counselling 2. NRT Combo + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling
Tzivoni 1998 ³¹⁷	Ciba-Geigy Ltd., Switzerland	Parallel RCT	2	2	Jerusalem, Israel	Yes	No	106	10 (9)		1. NRT Patch (24hrs) + Group Counselling 2. Placebo + Group Counselling
University of Michigan 2011 ³¹⁸		Parallel RCT	36	8	Michigan, USA	Yes	No	2485	1721 (69)	87	1. NRT Patch (24hrs) + Telephone Counselling 2. NRT Patch (24hrs) 3. No Drug Treatment
Uyar 2007 ³¹⁹		Parallel RCT	24	7	Turkey	Yes	No	131	25 (19)		1. Bupropion Standard + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling 3. No Drug Treatment + Individual Short Counselling
Velicer 2006 ³²⁰	National Cancer Institute Grant CA71356	Parallel RCT	128	6	Northeastern USA, USA	Yes	No	2054	473 (23)	89	1. No Drug Treatment 2. NRT Patch (16hrs) Standard 3. NRT Patch (16hrs) Standard 4. NRT Patch (16hrs) Standard + Telephone Short Counselling
Verplaetse 2016 ³²¹	NIH grants R01AA017976 (SAM) and NIAAA T32AA015496 (TLV)	Parallel RCT	1.14	1.14	Connecticut, USA	No	No	76	19 (25)	47	1. Placebo 2. Varenicline Low 3. Varenicline Standard
Wagena 2005 ³²²	Netherlands Asthma Foundation, Leusden and the Netherlands Organization for Health Research and Development, The Hague. Lundbeck BV, Amsterdam, the Netherlands, provided the nortriptyline free	Parallel RCT	27.6	12	Nijmegen, Netherlands	Yes	No	255	131 (51)	100	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo Individual + Telephone Short Counselling (Two out of three arms extracted)
Wallstrom 2000 ³²³	Pharmacia & Upjohn Consumer Health Care	Parallel RCT	52	24	Gothenburg, Sweden	Yes	No	247	146 (59)		1. NRT Sublingual Tablet + Individual Short Counselling 2. Placebo + Individual Short Counselling

Wang 2009 ³²⁴	Pfizer Inc	Parallel RCT	24	12	Thailand, China, Singapore	Yes	No	334	11 (3)	0	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Ward 2013 ³²⁵	PHS	Parallel RCT	52	6	Aleppo, Syria	Yes	No	269	58 (22)	0	1. NRT Patch (24hrs) + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling
Warner 2005 ³²⁶	Supported by grant No. RC 2002-0020 from the Minnesota Partnership for Action Against Tobacco, Minneapolis, Minnesota, and by funds from the Mayo Foundation, Rochester, Minnesota	Parallel RCT	25.71	4.29	Minnesota, USA	Yes	No	121	57 (47)	0	1. Placebo 2. NRT Patch (24hrs) High
Weaver 2015 ³²⁷	Wake Forest CCOP Research Base	Parallel RCT	24	6	USA	Yes	No	146	110 (75)	79	1. NRT + Individual + Telephone Short Counselling 2. Usual Care
Weinberger 2008 ³²⁸	National Institute on Drug Abuse grants R01-DA-13672 and K02-DA-16611 (to Dr George), K12-DA-000167 (to Dr Weinberger), Young Investigator (to Drs Sacco and Weinberger), and Independent investigator (to Dr George) awards from National Alliance for Research in Schizophrenia and Depression	Parallel RCT	10	10	Connecticut, USA	Yes	No	5	3 (60)	100	1. Bupropion Standard + Group Counselling 2. Placebo
Weiner 2011 ³²⁹	National Institutes on Drug Abuse Residential	Parallel RCT	12	12	USA	Yes	No	9	2 (22)	67	1. Varenicline Standard + Individual Counselling 2. Placebo + Individual Counselling

Research
Services
Contract
(N01DA5-9909
Kelly PI)

Weiner 2012 ³³⁰	Funded in part by the Veterans Affairs Capitol Network (VISN 5) Mental Illness Research, Education, and Clinical Center and National Institute of Mental Health Grant MH068580-01, Advance Center for Intervention Services Research	Parallel RCT	14	12	Maryland, USA	Yes	No	46	9 (20)	70	1. Bupropion Standard + Group Counselling 2. Placebo
Wennike 2003 ³³¹	Pharmacia AB, Sweden	Parallel RCT	104	52	Copenhagen, Denmark	No	No	411	255 (62)		1. NRT Gum + Individual Long Counselling 2. Placebo + Individual Long Counselling
Westergaard 2015 ³³²	Pfizer Inc.	Parallel RCT	24	12	Denmark		No	52	21 (40)		1. Varenicline Standard + Long Counselling 2. Placebo + Long Counselling
Westman 1993 ³³³	TBS Laboratories, Piscataway, NJ	Parallel RCT	24	6	North Carolina, USA	Yes	No	159	91 (57)	92	1. NRT Patch (24hrs) High + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Whelton 2012 ³³⁴	McNeil AB	Parallel RCT	12	12	Cork, Ireland	Yes	No	200	96 (48)		1. NRT Gum 2. NRT Sublingual Tablet
Wiggers 2006 ³³⁵	The Netherlands Heart Foundation	Parallel RCT	52	8	Amsterdam, The Netherlands	Yes	No	385	139 (36)		1. NRT Patch (24hrs) + Individual Long Counselling 2. NRT Patch (24hrs)
Williams 2007 ³³⁶	Pfizer	Parallel RCT	53	52	USA, Australia	Yes	No	377	189 (50)	89	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Williams 2012 ³³⁷	Pfizer	Parallel RCT	26	12	USA, Canada	Yes	No	128	29 (23)	59	1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Wilson 2008 ³³⁸		Parallel RCT	52	12	Northern Ireland, UK	Yes	No	91	47 (52)		1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Long Counselling 3. NRT Patch (16hrs) Standard + Group Long Counselling
Winhusen 2014 ³³⁹	National Institute on Drug Abuse	Parallel RCT	28	10.4	Oregon, Pennsylvania, South Carolina, Florida, Montana, Arizona,	Yes	No	538	258 (48)	60	1. Bupropion Standard + NRT Inhalator + Individual Short Counselling 2. Usual Care

Wiratmoko 2013 ³⁴⁰		Parallel RCT	24	12	California, Texas, USA Jakarta, Indonesia	Yes	No	80		1. Varenicline Standard + Counselling 2. Placebo + Counselling
Wittchen 2011 ³⁴¹	Federal Ministry of Education and Research, GlaxoSmithKline GmbH & Co. KG (Munich), GlaxoSmithKline Consumer Health Care GmbH & Co KG (Buehl) and Pharmacia GmbH (Erlangen)	Parallel RCT	52	12	greater Dresden and Munich, Germany	Yes	No	485	252 (52)	1. Bupropion Standard + Individual Long Counselling 2. No Drug Treatment + Individual Long Counselling 3. NRT Choice + Individual Long Counselling 4. No Drug Treatment + Individual Short Counselling
Wolfenden 2005 ³⁴²	National Heart Foundation, the Cancer Council NSW, and NSW Health through the Hunter Medical Research Institute	Parallel RCT	12	2	New South Wales, Australia	Yes	No	210	130 (62)	1. NRT + Individual + Telephone Short Counselling 2. NRT
Wong 1999 ³⁴³	DuPont Merck Pharmaceutical Company, Wilmington, Delaware	Parallel RCT	24	12	Minnesota, USA	Yes	No	100	53 (53)	1. Placebo + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Wong 2012 ³⁴⁴	Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto; University Health Network Foundation, Toronto, Ontario, Canada; and	Parallel RCT	52	12	Ontario, Canada	Yes	No	286	135 (47)	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling

Wong 2017³⁴⁵	Pfizer Canada Incorporated Funding from the Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada; University Health Network Foundation, Toronto, Ontario, Canada; and an investigator-initiated research grant from Pfizer Inc	Parallel RCT	52	12	Ontario, Canada	Yes	No	296	111 (38)	1. No Drug Treatment 2. Varenicline Standard + Individual + Telephone Short Counselling
YaleUniversity 2007³⁴⁶	Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Parallel RCT	1.14	1.14	Connecticut, USA	No	No	62	26 (42)	1. Varenicline Standard 2. Bupropion Standard 3. Placebo
Zellweger 2005³⁴⁷	GlaxoSmithKline	Parallel RCT	52	7	Austria, Estonia, Finland, Greece, Germany, Israel, Italy, Latvia, Lithuania, Poland, Spain, Switzerland	Yes	No	690	442 (64)	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Zernig 2008³⁴⁸	Styrian Regional Health Care System (Steiermaerkische Gebietskrankhe)	Parallel RCT	52	9	Graz, Austria	Yes	No	779	447 (57)	1. No Drug Treatment + Group Long Counselling 2. Bupropion Standard

	nkasse, STGKK), Austrian Science Fund										
Zhu 2016 ³⁴⁹	Grant from National Institute on Drug Abuse (DA012289) awarded to David G. Gilbert	Parallel RCT	2	2	Illinois, USA	Yes	No	110	54 (49)	89	1. Placebo 2. Bupropion Standard
ZYB 30011 ³⁵⁰	GlaxoSmithKline	Parallel RCT	24	7	Italy	Yes	No	254	87 (34)		1. Bupropion Standard 2. Placebo
ZYB40005 ³⁵¹	GlaxoSmithKline	Parallel RCT	52	33	USA	No	No	609	273 (45)	85	1. Bupropion Standard 2. Placebo
ZYB40030 ³⁵⁰	GlaxoSmithKline	Parallel RCT	9	9	Greece, Israel, Italy, and Turkey	Yes	No	314	119 (38)		1. Bupropion Standard 2. Placebo
ZYBAKIA402 ³⁵²	GlaxoSmithKline	Parallel RCT	52	12	USA	Yes	No	190	30 (16)	84	1. Bupropion Standard 2. Placebo

Table 2 Additional study characteristics for randomised controlled trials reporting safety outcomes

Study	Trial Registration	Population Studied	Smoking History M(SD)
Abelin 1989 ¹			22.2 (10.3)
Ahluwalia 1998 ²		Patients at a large inner-city hospital serving a low-income, predominantly African-American population	30
Ahluwalia 2002 ³		African-American smokers	
AKIA401 ⁴		Smokers who were male with at least 2 previous attempts to quit	
Allen 2011 ⁵		Smokers with schizophrenia	
Andrews 2016 ⁶	NCT01035151	Female smokers from subsidized housing neighbourhoods	
Anthenelli 2013 ⁷	NCT01078298	Smokers with current or past depression (major depressive disorder)	26.7 (11.8)
Anthenelli 2016A ⁸	NCT01456936		28.1 (12.8)
Anthenelli 2016B ⁸	NCT01456936	Smokers with psychiatric disorders	28.6 (11.9)
Anthonisen 1994 ⁹	NCT00000568	Smokers at high risk for chronic obstructive pulmonary disease	
Areechon 1988 ¹⁰			20.1
Aubin 2004 ¹¹			
Aubin 2008 ¹²	NCT00143325		25.6
Austin 2014 ¹³		Smokers who were not trying to quit	
Baker 2006 ¹⁴		Smokers with a non-acute psychotic disorder	
Baker 2016 ¹⁵	NCT01553084		28.6 (12)
Baldassarri 2018 ¹⁶	NCT02498145		
Batra 2005 ¹⁷		Smokers who had made at least 1 failed quit attempt within 2 years before the study but not within the previous 6 months	
Benowitz 2018 ¹⁸	NCT01574703	Smokers with and without psychiatric disorders	
Bernstein 2011 ¹⁹	NCT00297466	Smokers discharged from emergency departments	
Bernstein 2015 ²⁰	NCT01328431	Low-income smokers	
Bernstein 2016 ²¹	NCT02081144	Smokers discharged from emergency departments	
Binnie 2007 ²²			23.9 (8.1)
Bloch 2010 ²³		Smokers with schizophrenia or schizoaffective disorder	
Blondal 1999 ²⁴			
Bohadana 2000 ²⁵			20.6 (7.9)
Bolliger 2000 ²⁶		Smokers who have failed at least one serious attempt to quit within past year and want to use inhaler to reduce smoking	
Bolliger 2011 ²⁷	NCT00594204		
Boyle 1992 ²⁸		Smokeless tobacco users who had made at least one previous attempt to quit tobacco	12 (7.2)
Brandon 2011 ²⁹			25.3 (11.6)
Brantmark 1973 ³⁰	NCT00747643		18.5 (10.2)
Buchkremer 1988 ³¹			
Bullen 2010 ³²	ACTRN12605000373673		
Bullen 2013 ³³	ACTRN12610000866000		
Burstein 2006 ³⁴		Elderly smokers	47.6 (8.3)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Caldwell 2014 ³⁵			
Caldwell 2016 ³⁶	ACTRN12609000481279		
Campbell 1983 ³⁷		Smokers with a condition related to or aggravated by smoking (chronic bronchitis and emphysema, asthma, repeated respiratory infections, industrial lung disease, ischaemic heart disease, hypertension, peripheral vascular disease, and peptic ulcer)	
Campbell 1991 ³⁸		Former hospital inpatients (now outpatients) with smoking-related diseases; distribution of diagnoses (categories: heart disease, lung disease, peripheral vascular disease, peptic ulcer)	
Campbell 1996 ³⁹		Hospital inpatients and outpatients with smoking related respiratory or cardiovascular disease	31 (13)
Caponnetto 2013 ⁴⁰	NCT01164072	Smokers not currently or intending to quit smoking in the next 30 days	
Carpenter 2011 ⁴¹	NCT00706979	Smokers who were unmotivated to quit	
Carpenter 2017 ⁴²	NCT02357173		
Carson 2014 ⁴³		Smokers admitted to hospital with acute smoking-related illnesses	37.4 (2.9)
Chen 2013 ⁴⁴		Smokers with schizophrenia or schizoaffective disorder	21.6 (9.8)
Chengappa 2014 ⁴⁵	NCT01010204	Smokers with bipolar disorder	29.2 (11.2)
Christen 1984 ⁴⁶			16.4
Cinciripini 1996 ⁴⁷			25.3 (11.4)
Cinciripini 2013 ⁴⁸	NCT00507728		
Cinciripini 2018 ⁴⁹	NCT00943618		
Cooney 2009 ⁵⁰	NCT00064844	Alcohol-dependent tobacco smokers	
Cosci 2015 ⁵¹			4.8 (4.2)
Covey 2007 ⁵²		Smokers who had a previous quit attempt who were abstainers during the last 4 weeks of open-label treatment	
Cox 2012 ⁵³	NCT00666978	Light smokers	
Cravo 2016 ⁵⁴	NCT02029196		
Croghan 2003 ⁵⁵			23.3 (10.7)
Cummings 2011 ⁵⁶			
Cummins 2016 ⁵⁷	NCT01289275	Hospitalised smokers	
Dale 1995 ⁵⁸	NCT00235313		29.3 (11.7)
Dale 2002 ⁵⁹		Spit tobacco users	17.1 (11.4)
Dale 2007 ⁶⁰	NCT00414180	Smokeless tobacco users	19 (8.7)
Dalsgarð 2004 ⁶¹		Smokers including physicians, nurses, other hospital service and admin staff	
Daughton 1991 ⁶²			23.9
Daughton 1999/TNSG 1991 ⁶³		Smokers who had made at least one attempt to quit	24.1 (10.1)
Dautzenberg 2001 ⁶⁴			
Davidson 1998 ⁶⁵		Smokers who almost all reported at least 1 underlying illness at randomization (many of them reported several)	21 (11.5)

Study	Trial Registration	Population Studied	Smoking History M(SD)
deJong 2018 ⁶⁶	NCT01362959	Smokers who were mechanically ventilated in medical–surgical intensive care units	
Dogar 2018 ⁶⁷	ISRCTN94103375	Smokers using waterpipes	27.1 (15.9)
Du 2015 ⁶⁸	NCT01476202	Low dependence smokers	14.5 (10.4)
Ebbert 2007 ⁶⁹		Smokeless tobacco users	17 (7.5)
Ebbert 2009 ⁷⁰	NCT00392379	Smokeless tobacco users	16.3 (10.3)
Ebbert 2010 ⁷¹	NCT00888459	Smokeless tobacco users	17.8 (9.8)
Ebbert 2011 ⁷²	NCT00813917	Smokeless tobacco users	18.8 (11.3)
Ebbert 2013 ⁷³	NCT00939029	Smokeless tobacco users	18 (10)
Ebbert 2014 ⁷⁴	NCT00935818		23.4 (12.1)
Ebbert 2015 ⁷⁵	NCT01370356	Adult smokers unwilling to quit abruptly	
Ebbert 2017 ⁷⁶	NCT01639560	Light smokers	16.7 (11.3)
Ehrsam 1991 ⁷⁷			8.2 (3.3)
Eisenberg 2013 ⁷⁸	NCT00689611	Smokers hospitalized with enzyme positive acute myocardial infarction	32.9 (12.4)
	NCT00794573	Smokers hospitalised for acute coronary syndrome (myocardial infarction or unstable angina)	36 (12)
Eisenberg 2016 ⁷⁹	NCT02148445	Smokers with chronic lung disease/physician-diagnosed chronic obstructive pulmonary disease	
Ellerbeck 2018 ⁸⁰		Smokers who are unwilling to quit	
Etter 2002 ⁸¹			
Etter 2009 ⁸²	ISRCTN60585119		
Evins 2001 ⁸³		Smokers with schizophrenia	
Evins 2005 ⁸⁴		Smokers with schizophrenia or schizoaffective disorder depressed type	
Evins 2007 ⁸⁵	NCT00307203	Smokers with schizophrenia	26 (10.6)
Evins 2014 ⁸⁶	NCT00621777	Smokers with schizophrenia, schizoaffective disorder or bipolar disorder	
Fagerstrom 2010 ⁸⁷	NCT00717093	Smokeless tobacco users	21 (11.4)
Fatemi 2013 ⁸⁸	NCT01111149	Smokers with schizophrenia or schizoaffective disorder	
Fee 1982 ⁸⁹			
Ferry 1992 ⁹⁰			
Ferry 1994 ⁹¹		Non-depressed smokers	
Fiore 1994A ⁹²			24.8
Fiore 1994B ⁹²			25.1
Fortmann 1995 ⁹³		Smokers who reported success at quitting for 24 hours	
Fossati 2007 ⁹⁴		Smokers who were primary care patients	
Foulds 1993 ⁹⁵		Smokers who were outpatients	30.1 (12.5)
Fouz-Rosón 2017 ⁹⁶			
Fucito 2011 ⁹⁷	NCT00860028	Smokers who were heavy drinkers	19.3 (11.8)
Gariti 2009 ⁹⁸	NCT00086411	Light smokers	
Garvey 2000 ⁹⁹			
Garza 2011 ¹⁰⁰	NCT00749944		16.9
George 2002 ¹⁰¹		Smokers with schizophrenia or schizoaffective disorder	
George 2008 ¹⁰²	NCT00124683	Smokers with schizophrenia or schizoaffective disorder	22.6 (9.5)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Ginsberg 1992 ¹⁰³			
Glavas 2003A ¹⁰⁴		Healthcare professionals (doctors and nurses)	16.5 (4.4)
Glavas 2003B ¹⁰⁵			25 (5)
GlaxoSmithKline 2009 ¹⁰⁶	NCT00985985		
GlaxoSmithKline 2011 ¹⁰⁷	NCT01476202		
Glover 2002 ¹⁰⁸			25 (10.9)
Glover 2002 ¹⁰⁹		Smokeless tobacco users	
Gonzales 2001 ¹¹⁰		Smokers who previously used bupropion for at least 2 weeks without adverse effects	
Gonzales 2006 ¹¹¹	NCT00141206		24 (11.7)
Gonzales 2014 ¹¹²	NCT01244061	Smokers who had been previously treated with varenicline	30 (11.9)
Gourlay 1995 ¹¹³		Recently relapsed smokers (who had failed to quit in phase 1 of the trial)	23.7 (10.3)
Graham 2017 ¹¹⁴	NCT01544153; ISRCTN45127327		
Grant 2007 ¹¹⁵		Smokers meeting DSM-IV criteria for alcohol dependence/abuse	
Gray 2015 ¹¹⁶	NCT00664755	Female smokers	13.5 (7.8)
Haarmann 2016 ¹¹⁷	NCT01474265		
Haggström 2006 ¹¹⁸			
Hajek 2011 ¹¹⁹	NCT00789074		
Hajek 2013 ¹²⁰	NCT01184664		
Hajek 2015 ¹²¹	NCT01206010	Smokers who were non-responders to varenicline	
Hajek 2019 ¹²²	ISRCTN60477608		
Hall 2009 ¹²³	NCT00086385	Older cigarette smokers	37.8 (8.23)
Hall 2011 ¹²⁴			22.9 (10.1)
Hand 2002 ¹²⁵		Hospital inpatients or outpatients with smoking related disease	
Hanioka 2010 ¹²⁶			
Harackiewicz 1988 ¹²⁷			17
Hatsukami 2004 ¹²⁸		Smokers who want to reduce but not quit, at least 2 failed quit attempts including 1 with NRT	
Hawk 2012 ¹²⁹	NCT00835900		
Hays 1999 ¹³⁰			25.6 (11.6)
Hays 2001 ¹³¹		Smokers who quit after 7 weeks open label bupropion	
Hays 2009 ¹³²	NCT00000457	Smokers with a history of alcohol abuse or dependence and had at least 1 year of continuous abstinence from alcohol and drugs	25.5 (10.5)
Herrmann 2018 ¹³³		Smokers who were tobacco and cannabis co-users	
Hertzberg 2001 ¹³⁴		Male veteran smokers with PTSD	
Heydari 2012 ¹³⁵	IRCT138901111878N2	Previous quit-attempters	
Hilberink 2011 ¹³⁶	NCT00628225	Smokers with chronic obstructive pulmonary disease and were medicated	
Hilleman 1994 ¹³⁷		Smokers with a Fagerstrom score > 8 and at least one serious attempt to stop smoking in the past year	19.8 (9.1)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Hjalmarson 1984 ¹³⁸			
Hjalmarson 1994 ¹³⁹			26.8 (10.1)
		Smokers who have made a previous serious attempt to quit smoking using nicotine chewing gum	29.5 (9.5)
Hjalmarson 1997 ¹⁴⁰			
Holt 2005 ¹⁴¹		Indigenous Maori smokers	
	NCT00492349		
Hong 2011 ¹⁴²		Smokers and non-smokers with schizophrenia or schizoaffective disorder	
Howard-Pitney 1999 ¹⁴³		Smokeless tobacco users	
Hughes 1989 ¹⁴⁴			
Hughes 1999 ¹⁴⁵		Smokers who had made a prior attempt to stop smoking and were motivated to try again	26 (10)
Hughes 2003 ¹⁴⁶		Smokers with past alcohol dependence but no alcohol or illicit drug intake for last 30 days	
Hughes 2010 ¹⁴⁷	NCT00297492	Smokers wanting to quit in the next 30 days	
	NCT00595868		
Hughes 2011 ¹⁴⁸		Smokers who wished to quit at some point but had no current plans to quit smoking	26.4
Hurt 1990 ¹⁴⁹			
Hurt 1994 ¹⁵⁰			24.8 (10.6)
Hurt 1997 ¹⁵¹			
Hurt 2003 ¹⁵²			
Hurt 2018 ¹⁵³	NCT01347112	Smokers with alcohol dependence or abuse	
ICRF 1994 ¹⁵⁴			25
Ikonomidis 2017 ¹⁵⁵	NCT02307045		
Jain 2014 ¹⁵⁶	NCT01098305	Smokeless tobacco users	11.2 (7.6)
		Smokers from an earlier study of the effect of physician advice who had made one or more unsuccessful attempts to stop smoking over the preceding 12 months	
Jamrozik 1984 ¹⁵⁷			
Jarvis 1982 ¹⁵⁸			
		Smokers with vascular disease or persistent high cardiovascular disease risk	
Jennings 2014 ¹⁵⁹			
Jorenby 1995 ¹⁶⁰			
Jorenby 1999 ¹⁶¹			
Jorenby 2006 ¹⁶²	NCT00143364		25.6 (11.7)
		Smokers with a history of cardiac disease who had made a minimum of two previous attempts to quit; All subjects had one or more of the following diagnosed conditions: a history of myocardial infarction, a history of coronary-artery bypass surgery or angioplasty, stenosis of at least 50 percent in at least one major coronary artery as seen with coronary angiography, or a clinical history of angina, congestive heart failure, cor pulmonale, arrhythmia, peripheral vascular disease, or cerebrovascular disease.	44
Joseph 1996 ¹⁶³			
Joseph 2011 ¹⁶⁴	NCT00309296		
		Smokers with a history of alcohol dependence & ≥2m abstinence from alcohol & illicit drugs	
Kalman 2006 ¹⁶⁵			

Study	Trial Registration	Population Studied	Smoking History M(SD)
Kalman 2011 ¹⁶⁶	NCT00304707	Smokers with history of alcohol abuse or dependence with 2 to 12 months alcohol abstinence	
Karam-Hage 2011 ¹⁶⁷		Smokers with alcohol dependence	
Killen 1984 ¹⁶⁸			23.8 (10.4)
Killen 1999 ¹⁶⁹		Heavy smokers	
Killen 2006 ¹⁷⁰			
	NCT00632411	Smokers who were active duty Armed Forces personnel, or eligible reservists, National Guard members, retirees, or family members	18.9 (13.1)
Klesges 2015 ¹⁷¹			
Koegelenberg 2014 ¹⁷²	NCT01444131		26.4 (11.5)
Kornitzer 1995 ¹⁷³			
		Smokers who wanted to reduce their smoking, and had previously made at least one failed quit attempt	
Kralikova 2002 ¹⁷⁴			
Kupecz 1996 ¹⁷⁵			
	NCT01260233	Smokers were patients seen in the preadmission clinic at least 3 weeks preoperatively	27 (13.4)
Lee 2013 ¹⁷⁶			
Lee 2018 ¹⁷⁷	NCT02482233	Smokers awaiting elective surgery	32 (16)
Leischow 1996 ¹⁷⁸			25.9 (11.5)
Lerman 2004 ¹⁷⁹			
Lerman 2015 ¹⁸⁰	NCT01314001		
Levin 1994 ¹⁸¹			23.1 (9.3)
	NCT00006170	Female smokers who endorsed concern about postcessation weight gain	
Levine 2010 ¹⁸²			
Lewis 1998 ¹⁸³		Smokers who were hospital patients	26.4 (13.3)
		Smokers who were inpatients with schizophrenia	
Li 2009 ¹⁸⁴			
Lindson-Hawley 2014 ¹⁸⁵	ISRCTN33031001		
	NCT01146613	People with DSM IV TR alcohol dependence (n=76 smokers)	
Litten 2013 ¹⁸⁶			
Littlewood 2017 ¹⁸⁷			16.6 (10.1)
Llivina 1988 ¹⁸⁸			20.5 (12.5)
		Smokers with a diagnosis of ≥ 1 of the following conditions: heart disease (ie, coronary artery disease [CAD], congestive heart failure, mitral valve prolapse, and other cardiac conditions), recent heart attack, or irregular heartbeat; high blood pressure ($\geq 140/90$ mm Hg) not controlled by antihypertensive medication(s); and insulin-dependent or non-insulin-dependent diabetes mellitus	
Marsh 2005 ¹⁸⁹			
Masiero 2018 ¹⁹⁰	NCT02422914		
	NCT01621009; NCT01120704		
McCarthy 2008 ¹⁹¹			
McClure 2013 ¹⁹²	NCT00944554		25.5 (11.5)
McKee 2009 ¹⁹³		Heavy-drinking smokers	
Mercie 2018 ¹⁹⁴	NCT00918307	Smokers with HIV	26 (9)
Merz 1993 ¹⁹⁵			18.3 (9)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Meszaros 2013 ¹⁹⁶	NCT00727103	Schizophrenic patients and patients with schizoaffective disorder and co-occurring nicotine and alcohol dependence	
Mitchell 2012 ¹⁹⁷	NCT01011907	Heavy-drinking smokers	
Moller 2002 ¹⁹⁸		Smokers scheduled for surgery (primary elective hip or knee alloplasty)	
Molyneux 2003 ¹⁹⁹		Smokers admitted to medical and surgical wards	33.5 (16.2)
Mori 1992 ²⁰⁰		Smokers with smoking related illnesses	
Mulligan 1990 ²⁰¹			19
Myles 2004 ²⁰²		Smokers awaiting surgery	25 (12.5)
Myung 2007 ²⁰³			16.8 (5.8)
Nahvi 2014 ²⁰⁴	NCT01027754	Smokers in methadone treatment for substance abuse	
Nakamura 2007 ²⁰⁵	NCT00139750		20.9 (11.4)
NCT00365508 ²⁰⁶	NCT00365508	Smokers who were cancer patients	
NCT00828113 ²⁰⁷	NCT00828113		
NCT01010477 ²⁰⁸	NCT01010477	Smokers with schizophrenia	
NCT01055886 2009 ²⁰⁹	NCT01055886	Smokers with post-traumatic stress disorder (PTSD)	
Niaura 2008 ²¹⁰	NCT00150228		25.3
Nides 2006 ²¹¹	NCT00150241		24.1 (10.7)
Nides 2018 ²¹²	NCT02355665		
Nides 2018A ²¹³	NCT01466361		23.9 (11.3)
Nides 2018B ²¹³	NCT01506908		24.7 (12.1)
Olson 2009 ²¹⁴		Smokers planning to have pelvic or abdominal surgeries with a volatile anesthetic	
O'Malley 2017 ²¹⁵	NCT01553136	Smokers with alcohol use disorder	
Oncken 2006 ²¹⁶	NCT00150254		25 (10.6)
Oncken 2007 ²¹⁷		Postmenopausal women (i.e., with no menstruation for at least 1 year)	
Pack 2008 ²¹⁸			25.8 (11.9)
Paoletti 1996 ²¹⁹			
Pei 2014 ²²⁰		Smokers having total hip replacement surgery	
Perng 1998 ²²¹			34
Piper 2009 ²²²	NCT00332644		
Piper 2018 ²²³	NCT02301403	Smokers who were primary care patients	
Planer 2011 ²²⁴		Smokers with diagnosis of acute coronary syndrome	
Plebani 2013 ²²⁵	NCT00705523	People meeting DSM IV-TR criteria for alcohol dependence and reported drinking at least 12 out of last 30 days	
Poling 2010 ²²⁶	NCT00567320	Treatment seeking opioid dependent subjects who are smokers	
Ponciano-Rodriguez 2014 ²²⁷			33.4 (10.7)
Puska 1979 ²²⁸			
Puska 1995 ²²⁹			21.3 (8.6)
Ramon 2014 ²³⁰	NCT01538394		
Ratner 2004 ²³¹		Smokers who were patients admitted for pre-surgical assessment	34.2 (14)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Ray 2014 ²³²		Smokers who were heavy drinkers	
Reid 2003 ²³³		Smokers hospitalized for coronary artery disease	37.3 (9.3)
Rennard 1994 ²³⁴		Smokers with coronary artery disease	38.4 (9)
Rennard 2006 ²³⁵			
Rennard 2012 ²³⁶	NCT00691483	Smokers from research centres, private practice offices and research clinics	
Richmond 1994 ²³⁷			24 (10.8)
Rigotti 2006 ²³⁸	NCT00181818	Smokers hospitalised with cardiovascular disease	37.7 (11)
Rigotti 2010 ²³⁹	NCT00282984	Smokers with stable documented cardiovascular disease	40
Rodriguez-Artalejo 2003 ²⁴⁰			26.8 (8.6)
Rohsenow 2017 ²⁴¹	NCT00756275	Smokers diagnosed with substance use disorders	
Rose 1990 ²⁴²			
Rose 2009 ²⁴³			22.7 (9.8)
Rose 2013 ²⁴⁴	NCT00894166		
Rose 2014 ²⁴⁵	NCT01303861		26 (10.9)
Rose 2017 ²⁴⁶	NCT01806779		23.8 (10.9)
Rovina 2009 ²⁴⁷			
Rungruanghiranya 2008 ²⁴⁸			24.6 (10)
Russell 1983 ²⁴⁹			
Rutgers 2011 ²⁵⁰	NCT01308736		
Sachs 1993 ²⁵¹			28.6 (10.8)
SadrAzodi 2009 ²⁵²	NCT00533000	Smokers scheduled for surgery	
Schacht 2014 ²⁵³		Smokers and non-smokers with alcohol dependence	
Schmitz 2007 ²⁵⁴		Female smokers	28.5 (10.6)
Schneider 1983A ²⁵⁵			21.5
Schneider 1995 ²⁵⁶			22.3 (8.1)
Schneider 1996 ²⁵⁷			25.7 (11)
Schnoll 2010A ²⁵⁸	NCT00364156		
Schnoll 2010B ²⁵⁹			26.7 (12.9)
Schnoll 2013 ²⁶⁰	NCT00956943	Smokers who were fast nicotine metabolizers	
Schnoll 2015 ²⁶¹	NCT01047527		28.8 (12.6)
Schnoll 2019 ²⁶²	NCT01756885	Smokers with cancer	40.4 (11.3)
Schuermans 2004 ²⁶³		Smokers with 1 or more quit attempts in the last year	
		Smokers who were unable to quit or relapsed after previously taking bupropion for at least 2 weeks, not quit for more than 24 hours in the previous month	
Selby 2003 ²⁶⁴			
SelmaBozkurtZincir 2013 ²⁶⁵			
Severson 2015 ²⁶⁶	NCT01341938	Smokeless tobacco users	15.2 (9.8)
Sharma 2018 ²⁶⁷	NCT01517022	Smokers with tuberculosis	
Sheng 2013 ²⁶⁸		Smokers with at least one failed quit attempt	
Sherman 2008 ²⁶⁹		Smokers in the Veterans Health Administration	45
Shiffman 2002 ²⁷⁰			

Study	Trial Registration	Population Studied	Smoking History M(SD)
Shiffman 2006 ²⁷¹			21.9
Shiffman 2009 ²⁷²			26.8 (12.4)
	NCT00523445	Smokers and non-smokers with chronic schizophrenia who were clinically stable with less than moderate severity	21.2 (10.2)
Shim 2012 ²⁷³			
	NCT00135785	Smokers with methamphetamine dependence (48 (65.8%) of the 73 participants randomized)	
Shoptaw 2008 ²⁷⁴			
Siddiqi 2013 ²⁷⁵	ISRCTN08829879	Smokers with suspected tuberculosis	20.5 (12.3)
		Smokers who underwent noncardiac surgery and who were hospitalized for a minimum of 2 days	
Simon 1997 ²⁷⁶			
Simon 2004 ²⁷⁷		Smokers who were mostly (79%) veterans	
Simon 2009 ²⁷⁸	NCT00261170	Hospitalised smokers	
Singh 2010 ²⁷⁹			23.3 (13.8)
Smith 2009 ²⁸⁰	NCT00296647	Smokers who were primary care patients	
	NCT00802919	Smokers with schizophrenia or schizoaffective disorder	20.4 (11.4)
Smith 2016 ²⁸¹			
SMK20001 ²⁸²			
Sonderskov 1997 ²⁸³			21.2 (10.9)
		Smokers scheduled for an open colonic or rectal operative procedure with formation of an enteric anastomosis	
Sorensen 2003 ²⁸⁴			
SouthernIllinoisUniversityCarbondale 2005 ²⁸⁵	NCT01048944		
StanfordUniversity 2011 ²⁸⁶	NCT01413516	Smokers who were hospitalized patients	
Stapleton 1995 ²⁸⁷			
Stapleton 2011 ²⁸⁸	ISRCTN03150596	Smokers who were primary care patients	
Stapleton 2013 ²⁸⁹	ISRCTN91464711		
	NCT00790569	Methadone maintained opiate dependent smokers	23.3 (10.2)
Stein 2013 ²⁹⁰			
Steinberg 2009 ²⁹¹	NCT00770666	Medically ill smokers	
Steinberg 2011 ²⁹²		Hospitalised smokers	
Steinberg 2018 ²⁹³	NCT01308736		
Sutherland 1992 ²⁹⁴			22.6 (10)
Swan 2003 ²⁹⁵			26.6 (11.9)
		Smokers with stage I or stage II chronic obstructive pulmonary disease	
Tashkin 2001 ²⁹⁶			
	NCT00285012	Smokers with mild to moderate chronic obstructive pulmonary disease	40.5
Tashkin 2011 ²⁹⁷			
		Female smokers patients scheduled for breast cancer surgery	
Thomsen 2010 ²⁹⁸			
		Smokers with unmedicated major depression without psychotic features	27.9 (11)
Thorsteinsson 2001 ²⁹⁹			
	NCT00136760	Smokers with schizophrenia or schizoaffective disorder	26.4 (9.4)
Tidey 2011 ³⁰⁰			
Tonnesen 1988 ³⁰¹			
Tonnesen 1988 ³⁰²			
Tonnesen 1991 ³⁰³			26.3
Tonnesen 1993 ³⁰⁴			21 (11)
		Smokers who have made at least one prior quit attempt	
Tonnesen 1999 ³⁰⁵			
Tonnesen 2000 ³⁰⁶			

Study	Trial Registration	Population Studied	Smoking History M(SD)
Tonnesen 2003 ³⁰⁷			
Tonnesen 2006 ³⁰⁸		Smokers with chronic obstructive pulmonary disease	
Tønnesen 2012 ³⁰⁹	NCT00882375		
Tonstad 2003 ³¹⁰		Smokers with stable cardiovascular disease	
Tonstad 2006 ³¹¹	NCT00143286	Smokers from medical clinics	28.2 (10.5)
Tsai 2007 ³¹²	NCT00141167	Asian smokers	21.2
Tseng 2016 ³¹³		Young adult smokers	
Tsukahara 2010 ³¹⁴			26.3 (11.2)
Tuisku 2016 ³¹⁵	NCT01531049	Young adult smokers	6.4 (3)
Tulloch 2016 ³¹⁶	NCT01623505		31 (11.7)
Tzivoni 1998 ³¹⁷		Smokers with coronary artery disease	35.5
UniversityofMichigan 2011 ³¹⁸	NCT00534404		
Uyar 2007 ³¹⁹			
Velicer 2006 ³²⁰		Smokers who were members of a large northeastern U.S. Veterans Affairs Medical Center and smoking spouses	
Verplaetse 2016 ³²¹		Smokers with alcohol abuse or alcohol dependence and met criteria for heavy drinking	
Wagena 2005 ³²²		Smokers at risk for or with chronic obstructive pulmonary disease	
Wallstrom 2000 ³²³			26.5 (10.1)
Wang 2009 ³²⁴	NCT00371813		20.1
Ward 2013 ³²⁵	NCT01085032	Smokers who were primary care patients	
Warner 2005 ³²⁶		Smokers in preparation for elective surgery	
Weaver 2015 ³²⁷		Smokers who were cancer survivors	
Weinberger 2008 ³²⁸		Smokers with bipolar disorder	41.2 (9.8)
Weiner 2011 ³²⁹		Smokers with schizophrenia and schizoaffective disorder	27.8 (2.5)
Weiner 2012 ³³⁰	NCT00176449	Smokers with diagnosis of schizophrenia or schizoaffective disorder	
Wennike 2003 ³³¹		Smokers wanting to reduce smoking who failed a quit attempt in the last 24 months	28 (9.5)
Westergaard 2015 ³³²	NCT02233231	Young smokers with asthma	
Westman 1993 ³³³			22.6 (9)
Whelton 2012 ³³⁴	NCT01440985		
Wiggers 2006 ³³⁵		Smokers suffering from documented peripheral arterial disease or coronary artery disease	
Williams 2007 ³³⁶	NCT00143299		30.3
Williams 2012 ³³⁷	NCT00644969	Smokers with schizophrenia/schizoaffective disorder	24.3
Wilson 2008 ³³⁸		Smokers with chronic obstructive pulmonary disease	
Winhusen 2014 ³³⁹		Stimulant dependent smokers with substance use disorders	19.7 (9.9)
Wiratmoko 2013 ³⁴⁰			
Wittchen 2011 ³⁴¹			
Wolfenden 2005 ³⁴²		Smokers who were surgical patients having non-cardiac elective surgery and with pre-existing health problems requiring a pre-operative assessment	

Study	Trial Registration	Population Studied	Smoking History M(SD)
Wong 1999 ³⁴³			24.5 (10.6)
Wong 2012 ³⁴⁴	NCT00937508; NCT01320462 NCT01320462	Smokers from preoperative clinics who will undergo surgery in 8 to 30 days Smokers in the preoperative clinics scheduled for elective ambulatory or inpatient surgery	
Wong 2017 ³⁴⁵			
YaleUniversity 2007 ³⁴⁶	NCT00580853		
Zellweger 2005 ³⁴⁷		Healthcare professionals (qualified practising physician or nurse)	
Zernig 2008 ³⁴⁸	NCT00484692; EudraCT-Nr. 2005-006189-32		26.2 (11)
Zhu 2016 ³⁴⁹			
ZYB 30011 ³⁵⁰		Smokers with at least one cardiovascular risk factor	
ZYB40005 ³⁵¹		Smokers who were not motivated to quit smoking	
ZYB40030 ³⁵⁰		Smokers with chronic obstructive pulmonary disease	
ZYBAKIA402 ³⁵²		Smokers with ≥2 previous attempts to stop smoking	

- Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. *Lancet*. 1989;1(8628):7-10.
- Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. *J Gen Intern Med*. 1998;13(1):1-8.
- Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA*. 2002;288(4):468-74.
- AKIA401: A single-center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation in heavy smokers (study 401).
- Allen MH, Debanne M, Lazignac C, Adam E, Dickinson LM, Damsa C. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *Am J Psychiatry*. 2011;168(4):395-9.
- Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tingen MS. Effect of a smoking cessation intervention for women in subsidized neighborhoods: A randomized controlled trial. *Prev Med*. 2016;90:170-6.
- Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med*. 2013;159(6):390-400.
- Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet*. 2016;387(10037):2507-20.
- Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *Jama*. 1994;272(19):1497-505.
- Areechon W, Punnotok J. Smoking Cessation through the Use of Nicotine Chewing Gum - a Double-Blind Trial in Thailand. *Clinical Therapeutics*. 1988;10(2):183-6.
- Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. *Addiction*. 2004;99(9):1206-18.
- Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr., Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax*. 2008;63(8):717-24.
- Austin AJ, Duka T, Rusted J, Jackson A. Effect of varenicline on aspects of inhibitory control in smokers. *Psychopharmacology (Berl)*. 2014;231(18):3771-85.
- Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. *American Journal of Psychiatry*. 2006;163(11):1934-42.
- Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA*. 2016;315(4):371-9.
- Baldassarri SR, Bernstein SL, Chupp GL, Slade MD, Fucito LM, Toll BA. Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A pilot study. *Addict Behav*. 2018;80:1-5.
- Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. *Clin Pharmacol Ther*. 2005;78(6):689-96.
- Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. *JAMA Intern Med*. 2018;178(5):622-31.
- Bernstein SL, Bijur P, Cooperman N, Jearld S, Arnsten JH, Moadel A, et al. A randomized trial of a multicomponent cessation strategy for emergency department smokers. *Acad Emerg Med*. 2011;18(6):575-83.
- Bernstein SL, D'Onofrio G, Rosner J, O'Malley S, Makuch R, Busch S, et al. Successful Tobacco Dependence Treatment in Low-Income Emergency Department Patients: A Randomized Trial. *Ann Emerg Med*. 2015;66(2):140-7.
- Bernstein SL, Rosner J, Toll B. A Multicomponent Intervention Including Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study. *Acad Emerg Med*. 2016;23(7):803-8.
- Binnie VI, McHugh S, Jenkins W, Borland W, Macpherson LM. A randomised controlled trial of a smoking cessation intervention delivered by dental hygienists: a feasibility study. *BMC Oral Health*. 2007;7:5.
- Bloch B, Reshef A, Cohen T, Tafla A, Gathas S, Israel S, et al. Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. *Psychiatry Res*. 2010;175(1-2):38-42.
- Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ*. 1999;318(7179):285-8.
- Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med*. 2000;160(20):3128-34.
- Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. *BMJ*. 2000;321(7257):329-33.

27. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther*. 2011;33(4):465-77.
28. Boyle R, Severson H, Lichtenstein E, et al. Smokeless tobacco cessation with nicotine reduction: A placebo controlled trial [abstract]. Paper presented at: 121st Annual Meeting Location: San Francisco, CA. 1992.
29. Brandon TH, Drobos DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, et al. Varenicline effects on craving, cue reactivity, and smoking reward. *Psychopharmacology (Berl)*. 2011;218(2):391-403.
30. Brantmark B, Ohlin P, Westling H. Nicotine-containing chewing gum as an anti-smoking aid. *Psychopharmacologia*. 1973;31(3):191-200.
31. Buchkremer G, Bents H, Horstmann M, Opitz K, Tölle R. Combination of behavioral smoking cessation with transdermal nicotine substitution. *Addictive Behaviors*. 1989;14(2):229-38.
32. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. *Addiction*. 2010;105(8):1474-83.
33. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: A randomised controlled trial. *The Lancet*. 2013;382(9905):1629-37.
34. Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. *J Clin Pharmacol*. 2006;46(11):1234-40.
35. Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. *Nicotine Tob Res*. 2014;16(10):1356-64.
36. Caldwell BO, Crane J. Combination Nicotine Metered Dose Inhaler and Nicotine Patch for Smoking Cessation: A Randomized Controlled Trial. *Nicotine Tob Res*. 2016;18(10):1944-51.
37. Campbell IA. Comparison of 4 Methods of Smoking Withdrawal in Patients with Smoking Related Diseases. *British Medical Journal*. 1983;286(6365):595-7.
38. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. *Respir Med*. 1991;85(2):155-7.
39. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. *Respir Med*. 1996;90(1):47-51.
40. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and Safety of an eElectronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. *PLoS One*. 2013;8(6):e66317.
41. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. *Arch Intern Med*. 2011;171(21):1901-7.
42. Carpenter MJ, Heckman BW, Wahlquist AE, Wagener TL, Goniewicz ML, Gray KM, et al. A Naturalistic, Randomized Pilot Trial of E-Cigarettes: Uptake, Exposure, and Behavioral Effects. *Cancer Epidemiol Biomarkers Prev*. 2017;26(12):1795-803.
43. Carson KV, Smith BJ, Brinn MP, Peters MJ, Fitridge R, Koblar SA, et al. Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study). *Nicotine Tob Res*. 2014;16(11):1495-502.
44. Chen HK, Lan TH, Wu BJ. A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. *Eur Arch Psychiatry Clin Neurosci*. 2013;263(1):75-82.
45. Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2014;75(7):765-72.
46. Christen AG, McDonald JL, Jr., Olson BL, Drook CA, Stookey GK. Efficacy of nicotine chewing gum in facilitating smoking cessation. *J Am Dent Assoc*. 1984;108(4):594-7.
47. Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. *J Consult Clin Psychol*. 1996;64(2):314-23.
48. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry*. 2013;70(5):522-33.
49. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction*. 2018.
50. Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction*. 2009;104(9):1588-96.
51. Cosci F, Ibrahim HM, Nannini A, Schruers K. Experimental study on the effects of anxiety sensitivity and somatosensory amplification on the response to the 35% CO(2) challenge in abstinent smokers. *Exp Clin Psychopharmacol*. 2015;23(6):464-76.
52. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. *Addiction*. 2007;102(8):1292-302.
53. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. *J Natl Cancer Inst*. 2012;104(4):290-8.
54. Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. *Regul Toxicol Pharmacol*. 2016;81 Suppl 1:S1-S14.
55. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. *Nicotine Tob Res*. 2003;5(2):181-7.
56. Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, Willett J, Juster HR. Costs of giving out free nicotine patches through a telephone quit line. *J Public Health Manag Pract*. 2011;17(3):E16-23.
57. Cummins SE, Gamst AC, Brandstein K, Seymann GB, Klonoff-Cohen H, Kirby CA, et al. Helping Hospitalized Smokers: A Factorial RCT of Nicotine Patches and Counseling. *Am J Prev Med*. 2016;51(4):578-86.
58. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. *JAMA*. 1995;274(17):1353-8.
59. Dale LC, Ebbert JO, Schroeder DR, Croghan IT, Rasmussen DF, Trautman JA, et al. Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study. *Nicotine Tob Res*. 2002;4(3):267-74.
60. Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, et al. Bupropion SR for the treatment of smokeless tobacco use. *Drug Alcohol Depend*. 2007;90(1):56-63.
61. Dalsgareth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. *Nicotine Tob Res*. 2004;6(1):55-61.
62. Daughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy - a Randomized, Placebo-Controlled, Double-Blind-Study. *Archives of Internal Medicine*. 1991;151(4):749-52.
63. Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. *Prev Med*. 1999;28(2):113-8.
64. Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL, et al. First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomised clinical trial. *European Respiratory Journal*. 2001;18 Suppl 33:12s.
65. Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. *Archives of Family Medicine*. 1998;7(6):569-74.
66. de Jong B, Schuppers AS, Kruisdijk-Gerritsen A, Arbouw MEL, van den Oever HLA, van Zanten ARH. The safety and efficacy of nicotine replacement therapy in the intensive care unit: a randomised controlled pilot study. *Ann Intensive Care*. 2018;8(1):70.
67. Dogar O, Zahid R, Mansoor S, Kanaan M, Ahluwalia JS, Jawad M, et al. Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial. *Addiction*. 2018;113(12):2290-9.
68. Du D, Borders J, Selmani A, Wawerczak W. A Pilot Study to Investigate the Efficacy of Nicotine Oral Soluble Film, Lozenge and Gum in Relief of Acute Smoking Cue-provoked Craving for Cigarette in Low Dependence Smokers. *Journal of Smoking Cessation*. 2015;10(2):87-95.
69. Ebbert JO, Dale LC, Patten CA, Croghan IT, Schroeder DR, Moyer TP, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. *Nicotine Tob Res*. 2007;9(1):43-52.
70. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. *Nicotine Tob Res*. 2009;11(12):1415-23.
71. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users. *Addict Behav*. 2010;35(5):522-5.

72. Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. *Nicotine Tob Res.* 2011;13(9):820-6.
73. Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. *Nicotine Tob Res.* 2013;15(12):2037-44.
74. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA.* 2014;311(2):155-63.
75. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. *JAMA.* 2015;313(7):687-94.
76. Ebbert J, Croghan I, Hurt R, Schroeder D, Hays J. Varenicline for smoking cessation in light smokers 2017; 18(10):[2031-5 pp.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/1471-2575.t1100001>
77. Ehrensam RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H, et al. [Weaning of young smokers using a transdermal nicotine patch]. *Schweiz Rundsch Med Prax.* 1991;80(7):145-50.
78. Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. *J Am Coll Cardiol.* 2013;61(5):524-32.
79. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation.* 2016;133(1):21-30.
80. Ellerbeck EF, Nollen N, Hutcheson TD, Phadnis M, Fitzgerald SA, Vacek J, et al. Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. *JAMA Netw Open.* 2018;1(5):e181843.
81. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *J Clin Psychopharmacol.* 2002;22(5):487-95.
82. Etter JF, Huguélet P, Perneger TV, Cornuz J. Nicotine Gum Treatment Before Smoking Cessation A Randomized Trial. *Archives of Internal Medicine.* 2009;169(11):1028-34.
83. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine Tob Res.* 2001;3(4):397-403.
84. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol.* 2005;25(3):218-25.
85. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol.* 2007;27(4):380-6.
86. Evins AE, Cather C, Pratt SA, Pachas GN, Hoepfner SS, Goff DC, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA.* 2014;311(2):145-54.
87. Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. *BMJ.* 2010;341:c6549.
88. Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study. *Schizophr Res.* 2013;146(1-3):376-8.
89. Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. *Practitioner.* 1982;226(1363):148-51.
90. Ferry LH, Robbins AS, Scariati PD, Masterson A, Abbey DE, Burchette RJ. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride [abstract 2670]. *Circulation.* 1992;86(4 Suppl 1):I-671.
91. Ferry LH, Burchette RJ. Efficacy of Bupropion for Smoking Cessation in Non Depressed Smokers. *Journal of Addictive Diseases.* 1994;13(4):249-.
92. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. *Chest.* 1994;105(2):524-33.
93. Fortmann SP, Killen JD. Nicotine Gum and Self-Help Behavioral Treatment for Smoking Relapse Prevention - Results from a Trial Using Population-Based Recruitment. *Journal of Consulting and Clinical Psychology.* 1995;63(3):460-8.
94. Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. *Arch Intern Med.* 2007;167(16):1791-7.
95. Foulds J, Stapleton J, Hayward M, Russell MA, Feyerabend C, Fleming T, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. A placebo-controlled trial. *Arch Fam Med.* 1993;2(4):417-23.
96. Fouz-Roson N, Montemayor-Rubio T, Almadana-Pacheco V, Montserrat-Garcia S, Gomez-Bastero AP, Romero-Munoz C, et al. Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. *Addiction.* 2017;112(9):1610-9.
97. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. *Psychopharmacology (Berl).* 2011;215(4):655-63.
98. Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. *J Subst Abuse Treat.* 2009;37(3):247-55.
99. Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine Tob Res.* 2000;2(1):53-63.
100. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. *Biol Psychiatry.* 2011;69(11):1075-82.
101. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. *Biol Psychiatry.* 2002;52(1):53-61.
102. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. *Biol Psychiatry.* 2008;63(11):1092-6.
103. Ginsberg D, Hall SM, Rosinski M. Partner support, psychological treatment, and nicotine gum in smoking treatment: an incremental study. *Int J Addict.* 1992;27(5):503-14.
104. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: Randomized double-blind study. *Croatian Medical Journal.* 2003;44(2):219-24.
105. Glavas D, Rumboldt Z. [Smoking cessation using the transdermal nicotine system]. *Lijec Vjesn.* 2003;125(1-2):8-12.
106. GlaxoSmithKline. Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation. <https://ClinicalTrials.gov/show/NCT00985985>; 2009.
107. GlaxoSmithKline. Provoked Craving Relief Study by NRT. <https://ClinicalTrials.gov/show/NCT01476202>; 2011.
108. Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine Tob Res.* 2002;4(4):441-50.
109. Glover ED, Glover PN, Sullivan CR, Cerullo CL, Hobbs G. A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation. *Am J Health Behav.* 2002;26(5):386-93.
110. Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. *Clin Pharmacol Ther.* 2001;69(6):438-44.
111. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):47-55.
112. Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. *Clin Pharmacol Ther.* 2014;96(3):390-6.
113. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. *BMJ.* 1995;311(7001):363-6.
114. Graham AL, Papandonatos GD, Cha S, Erar B, Amato MS, Cobb NK, et al. Improving Adherence to Smoking Cessation Treatment: Intervention Effects in a Web-Based Randomized Trial. *Nicotine Tob Res.* 2017;19(3):324-32.
115. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ. Bupropion and nicotine patch as smoking cessation aids in alcoholics. *Alcohol.* 2007;41(5):381-91.

116. Gray KM, McClure EA, Baker NL, Hartwell KJ, Carpenter MJ, Saladin ME. An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. *Addiction*. 2015;110(6):1027-34.
117. Haarmann H, Gossler A, Herrmann P, Bonev S, Nguyen XP, Hasenfuss G, et al. Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial. *Tob Induc Dis*. 2016;14:26.
118. Haggstram FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. *Pulm Pharmacol Ther*. 2006;19(3):205-9.
119. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. *Arch Intern Med*. 2011;171(8):770-7.
120. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. *BMC Med*. 2013;11:140.
121. Hajek P, McRobbie H, Myers Smith K, Phillips A, Cornwall D, Dhanji AR. Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial. *JAMA Intern Med*. 2015;175(2):266-71.
122. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *N Engl J Med*. 2019;380(7):629-37.
123. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. *Addiction*. 2009;104(6):1043-52.
124. Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska JJ, Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent smokers. *Am J Public Health*. 2011;101(12):2349-56.
125. Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. *Thorax*. 2002;57(8):715-8.
126. Hanioka T, Ojima M, Tanaka H, Naito M, Hamajima N, Matsuse R. Intensive smoking-cessation intervention in the dental setting. *J Dent Res*. 2010;89(1):66-70.
127. Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. *Addict Behav*. 1988;13(4):319-30.
128. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. *Am J Med*. 2004;116(3):151-7.
129. Hawk LW, Jr., Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, et al. The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial. *Clin Pharmacol Ther*. 2012;91(2):172-80.
130. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. *Am J Public Health*. 1999;89(11):1701-7.
131. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. *Ann Intern Med*. 2001;135(6):423-33.
132. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. *Nicotine Tob Res*. 2009;11(7):859-67.
133. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, et al. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. *Addict Biol*. 2019;24(4):765-76.
134. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. *J Clin Psychopharmacol*. 2001;21(1):94-8.
135. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. *Int J Tuberc Lung Dis*. 2012;16(2):268-72.
136. Hilberink SR, Jacobs JE, Breteler MH, de Vries H, Grol RP. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. *Patient Educ Couns*. 2011;83(1):120-4.
137. Hilleman DE, Mohiuddin SM, Delcore MG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. *J Clin Pharmacol*. 1994;34(3):222-4.
138. Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. *JAMA*. 1984;252(20):2835-8.
139. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med*. 1994;154(22):2567-72.
140. Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O. The nicotine inhaler in smoking cessation. *Arch Intern Med*. 1997;157(15):1721-8.
141. Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropion in the indigenous Maori population in New Zealand. *Thorax*. 2005;60(2):120-3.
142. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry*. 2011;68(12):1195-206.
143. Howard-Pitney B, Killen JD, Fortmann SP. Quitting chew: results from a randomized trial using nicotine patches. *Exp Clin Psychopharmacol*. 1999;7(4):362-71.
144. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. *JAMA*. 1989;261(9):1300-5.
145. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? *Nicotine Tob Res*. 1999;1(2):169-74.
146. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. *Alcohol Clin Exp Res*. 2003;27(6):946-54.
147. Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN. A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. *Drug Alcohol Depend*. 2010;111(1-2):105-13.
148. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. *Nicotine Tob Res*. 2011;13(10):955-64.
149. Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-Replacement Therapy with Use of a Transdermal Nicotine Patch - a Randomized Double-Blind Placebo-Controlled Trial. *Mayo Clinic Proceedings*. 1990;65(12):1529-37.
150. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. *JAMA*. 1994;271(8):595-600.
151. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med*. 1997;337(17):1195-202.
152. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J Clin Oncol*. 2003;21(5):914-20.
153. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. *Drug Alcohol Depend*. 2018;184:12-7.
154. Randomised trial of nicotine patches in general practice: results at one year. Imperial Cancer Research Fund General Practice Research Group. *BMJ*. 1994;308(6942):1476-7.
155. Ikonomidis I, Marinou M, Vlastos D, Kourea K, Andreadou I, Liarakos N, et al. Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. *Atherosclerosis*. 2017;262:123-30.
156. Jain R, Jhanjee S, Jain V, Gupta T, Mittal S, Goelz P, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. *Nicotine Tob Res*. 2014;16(1):50-7.
157. Jamrozik K, Fowler G, Vessey M, Wald N. Placebo controlled trial of nicotine chewing gum in general practice. *Br Med J (Clin Res Ed)*. 1984;289(6448):794-7.
158. Jarvis MJ, Raw M, Russell MAH, Feyerabend C. Randomized Controlled Trial of Nicotine Chewing-Gum. *British Medical Journal*. 1982;285(6341):537-40.
159. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferrero S, et al. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. *Eur Heart J*. 2014;35(21):1411-20.
160. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. *JAMA*. 1995;274(17):1347-52.
161. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*. 1999;340(9):685-91.

162. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):56-63.
163. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. *N Engl J Med*. 1996;335(24):1792-8.
164. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. *Arch Intern Med*. 2011;171(21):1894-900.
165. Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. *J Subst Abuse Treat*. 2006;30(3):213-7.
166. Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. *Drug Alcohol Depend*. 2011;118(2-3):111-8.
167. Karam-Hage M, Strobbe S, Robinson JD, Brower KJ. Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind pilot study. *Am J Drug Alcohol Abuse*. 2011;37(6):487-90.
168. Killen JD, Maccoby N, Taylor CB. Nicotine Gum and Self-Regulation Training in Smoking Relapse Prevention. *Behavior Therapy*. 1984;15(3):234-48.
169. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? *Experimental and Clinical Psychopharmacology*. 1999;7(3):226-33.
170. Killen JD, Fortmann SP, Murphy GM, Jr., Hayward C, Arredondo C, Crompton D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. *J Consult Clin Psychol*. 2006;74(2):286-94.
171. Klesges RC, Ebbert JO, Talcott GW, Thomas F, Richey PA, Womack C, et al. Efficacy of a Tobacco Quitline in Active Duty Military and TRICARE Beneficiaries: A Randomized Trial. *Mil Med*. 2015;180(8):917-25.
172. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA*. 2014;312(2):155-61.
173. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med*. 1995;24(1):41-7.
174. Kralikova E, Kozak J, Rasmussen T, Cort N. The clinical benefits of NRT-supported smoking reduction. *Nicotine Tob Res*. 2002;4(243):20.
175. Kupecz D, Prochazka A. A comparison of nicotine delivery systems in a multimodality smoking cessation program. *Nurse Pract*. 1996;21(2):73, 7-8, 81 passim.
176. Lee SM, Landry J, Jones PM, Buhmann O, Morley-Forster P. The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. *Anesth Analg*. 2013;117(3):605-13.
177. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. *PeerJ*. 2018;6:e5609.
178. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *American Journal of Health Behavior*. 1996;20(5):364-71.
179. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. *Ann Intern Med*. 2004;140(6):426-33.
180. Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med*. 2015;3(2):131-8.
181. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S, et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. *J Clin Psychopharmacol*. 1994;14(1):41-9.
182. Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. *Arch Intern Med*. 2010;170(6):543-50.
183. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. *Prev Med*. 1998;27(2):296-303.
184. Li J, Zhang T-I, Wang B, Li X-w. An efficacy analysis of bupropion for smoking cessation in schizophrenia. *Zhongguo Xinyao yu Linchuang Zazhi*. 2009;28(3):231-4.
185. Lindson-Hawley N, Coleman T, Docherty G, Hajek P, Lewis S, Lycett D, et al. Nicotine patch preloading for smoking cessation (the preloading trial): study protocol for a randomized controlled trial. *Trials*. 2014;15(296):296.
186. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. *J Addict Med*. 2013;7(4):277-86.
187. Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, et al. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. *Psychopharmacology (Berl)*. 2017;234(23-24):3417-29.
188. Livina TS, Tuya DM, Quintana JG, Torres CI, Barrera EC, Saez CM, et al. Smoking Cessation - Effectiveness of Nicotine Containing Chewing Gum - a Double-Blind Trial. *Medicina Clinica*. 1988;90(16):646-50.
189. Marsh HS, Dresler CM, Choi JH, Targett DA, Gamble ML, Strahs KR. Safety profile of a nicotine lozenge compared with that of nicotine gum in adult smokers with underlying medical conditions: a 12-week, randomized, open-label study. *Clin Ther*. 2005;27(10):1571-87.
190. Masiero M, Lucchiari C, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, et al. E-cigarettes May Support Smokers With High Smoking-Related Risk Awareness to Stop Smoking in the Short Run: Preliminary Results by Randomized Controlled Trial. *Nicotine Tob Res*. 2019;21(1):119-26.
191. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine Tob Res*. 2008;10(4):717-29.
192. McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of varenicline on abstinence and smoking reward following a programmed lapse. *Nicotine Tob Res*. 2013;15(1):139-48.
193. McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetraault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. *Biol Psychiatry*. 2009;66(2):185-90.
194. Mercie P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. *Lancet HIV*. 2018;5(3):E126-E35.
195. Merz PG, Kellerstanislawski B, Huber T, Woodcock BG, Rietbrock N. Transdermal Nicotine in Smoking Cessation and Involvement of Nonspecific Influences. *International Journal of Clinical Pharmacology and Therapeutics*. 1993;31(10):476-82.
196. Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial. *J Clin Psychopharmacol*. 2013;33(2):243-7.
197. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. *Psychopharmacology (Berl)*. 2012;223(3):299-306.
198. Moller AM, Villebro N, Pedersen T, Tonnesen H. Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. *Lancet*. 2002;359(9301):114-7.
199. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniuk M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. *Thorax*. 2003;58(6):484-8.
200. Mori T STYGNMHT. A clinical trial of nicotine chewing gum for smoking cessation [abstract 428]. 1992.
201. Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. *Clin Pharmacol Ther*. 1990;47(3):331-7.
202. Myles PS, Leslie K, Angliss M, Mezzavia P, Lee L. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. *Anaesthesia*. 2004;59(11):1053-8.
203. Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee DH, et al. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. *J Korean Med Sci*. 2007;22(6):1065-70.
204. Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. *Addiction*. 2014;109(9):1554-63.

205. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. *Clin Ther.* 2007;29(6):1040-56.
206. Fox Chase Cancer Center, National Cancer Institute. Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking. <https://ClinicalTrials.gov/show/NCT00365508>; 2006.
207. Pfizer. Long-term Varenicline Treatment for Smoking Cessation. University of Wisconsin, Madison: <https://ClinicalTrials.gov/show/NCT00828113>; 2009.
208. Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia. <https://ClinicalTrials.gov/show/NCT01010477>; 2009.
209. Duke University. Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD). 2009.
210. Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. *Curr Med Res Opin.* 2008;24(7):1931-41.
211. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. *Arch Intern Med.* 2006;166(15):1561-8.
212. Nides M, Danielsson T, Saunders F, Perfekt R, Kapikian R, Solla J, et al. Efficacy and safety of a nicotine mouth spray for smoking cessation; a randomized, multicenter, controlled study in a naturalistic setting. *Nicotine Tob Res.* 2018;18:18.
213. Nides M, Shanga GM, Bishop A, Becker WD. Nicotine Lozenges in the Relief of Behaviorally Provoked Craving. *Am J Health Behav.* 2018;42(3):69-80.
214. Olson LC, Hong D, Conell-Price JS, Cheng S, Flood P. A transdermal nicotine patch is not effective for postoperative pain management in smokers: a pilot dose-ranging study. *Anesth Analg.* 2009;109(6):1987-91.
215. O'Malley S, Zweben A, Fucito L, Wu R, Piepmeier M, Ockert D, et al. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: a Randomized Clinical Trial 2017; 75(2):[129-38 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/299/CN-01457299/frame.html>.
216. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med.* 2006;166(15):1571-7.
217. Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. *Addict Behav.* 2007;32(2):296-309.
218. Pack QR, Jorenby DE, Fiore MC, Jackson T, Weston P, Piper ME, et al. A comparison of the nicotine lozenge and nicotine gum: an effectiveness randomized controlled trial. *WMJ.* 2008;107(5):237-43.
219. Paoletti P, Fornai E, Maggiorini F, Puntoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. *Eur Respir J.* 1996;9(4):643-51.
220. Pei H, Zhang LJ, Zeng LM, Yu F. Effect of preoperative smoking intervention on postoperative complications of total hip replacement. [Chinese]. *Chinese Journal of Evidence-Based Medicine.* 2014;14(4):399-403.
221. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. *J Formos Med Assoc.* 1998;97(8):547-51.
222. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry.* 2009;66(11):1253-62.
223. Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Collins LM, et al. A Randomized Controlled Trial of an Optimized Smoking Treatment Delivered in Primary Care. *Ann Behav Med.* 2018;52(10):854-64.
224. Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. *Arch Intern Med.* 2011;171(12):1055-60.
225. Plebani JG, Lynch KG, Rennert L, Pettinati HM, O'Brien CP, Kampman KM. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. *Drug Alcohol Depend.* 2013;133(2):754-8.
226. Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. *Am J Addict.* 2010;19(5):401-8.
227. Ponciano-Rodriguez G, Paez-Martinez N, Villa-Romero A, Gutierrez-Grobe Y, Mendez-Sanchez N. Early changes in the components of the metabolic syndrome in a group of smokers after tobacco cessation. *Metab Syndr Relat Disord.* 2014;12(4):242-50.
228. Puska P, Bjorkqvist S, Koskela K. Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up. *Addict Behav.* 1979;4(2):141-6.
229. Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation - a clinical trial in North Karelia. *Tobacco Control.* 1995;4(3):231-5.
230. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med.* 2014;12(172):172.
231. Ratner PA, Johnson JL, Richardson CG, Bottorff JL, Moffat B, Mackay M, et al. Efficacy of a smoking-cessation intervention for elective-surgical patients. *Res Nurs Health.* 2004;27(3):148-61.
232. Ray LA, Courtney KE, Ghahremani DG, Miotto K, Brody A, London ED. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. *Psychopharmacology (Berl).* 2014;231(19):3843-53.
233. Reid R, Pipe A, Higginson L, Johnson K, D'Angelo MS, Cooke D, et al. Stepped care approach to smoking cessation in patients hospitalized for coronary artery disease. *J Cardiopulm Rehabil.* 2003;23(3):176-82.
234. Rennard S, Daughton D, Cheney R, Thompson A, Miles R, Windle J, et al. Nicotine Replacement Therapy for Patients with Coronary-Artery Disease. *Archives of Internal Medicine.* 1994;154(9):989-95.
235. Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. *Nicotine Tob Res.* 2006;8(4):555-64.
236. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res.* 2012;14(3):343-50.
237. Richmond RL, Harris K, Dealmeidaneto A. The Transdermal Nicotine Patch - Results of a Randomized Placebo-Controlled Trial. *Medical Journal of Australia.* 1994;161(2):130-&.
238. Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. *Am J Med.* 2006;119(12):1080-7.
239. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation.* 2010;121(2):221-9.
240. Rodriguez-Artalejo F, Lafuente Urduinguio P, Guallar-Castillon P, Garteizaurreakoa Dublang P, Sainz Martinez O, Diez Azcarate JI, et al. One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial. *Occup Environ Med.* 2003;60(5):358-63.
241. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. *Addiction.* 2017;112(10):1808-20.
242. Rose JE, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. *Clin Pharmacol Ther.* 1990;47(3):323-30.
243. Rose JE, Herskovic JE, Behm FM, Westman EC. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. *Nicotine Tob Res.* 2009;11(9):1067-75.
244. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. *Am J Psychiatry.* 2013;170(8):860-7.
245. Rose JE, Behm FM. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. *Am J Psychiatry.* 2014;171(11):1199-205.
246. Rose JE, Behm FM. Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. *Nicotine Tob Res.* 2017;19(8):999-1002.
247. Rovina N, Nikoloutsou I, Katsani G, Dima E, Fransis K, Roussos C, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. *Ther Adv Respir Dis.* 2009;3(6):279-87.
248. Rungruanghiranya S, Ekpanyaskul C, Hattapornsawan Y, Tundulawessa Y. Effect of nicotine polyestex gum on smoking cessation and quality of life. *J Med Assoc Thai.* 2008;91(11):1656-62.
249. Russell MAH, Merriman R, Stapleton J, Taylor W. Effect of Nicotine Chewing Gum as an Adjunct to General-Practitioners Advice against Smoking. *British Medical Journal.* 1983;287(6407):1782-5.
250. Rutgers TSUoNJ, Pfizer. Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit. <https://ClinicalTrials.gov/show/NCT01308736>; 2011.

251. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-Hour Transdermal Nicotine Patch in a Medical-Practice Setting, without Intensive Group-Counseling. *Archives of Internal Medicine*. 1993;153(16):1881-90.
252. Sadr Azodi O, Lindstrom D, Adami J, Tonnesen H, Nasell H, Gilljam H, et al. The efficacy of a smoking cessation programme in patients undergoing elective surgery: a randomised clinical trial. *Anaesthesia*. 2009;64(3):259-65.
253. Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H. Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. *Psychopharmacology (Berl)*. 2014;231(18):3799-807.
254. Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF. Bupropion and cognitive-behavioral therapy for smoking cessation in women. *Nicotine Tob Res*. 2007;9(6):699-709.
255. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav*. 1983;8(3):253-61.
256. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction*. 1995;90(12):1671-82.
257. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction*. 1996;91(9):1293-306.
258. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. *Ann Intern Med*. 2010;152(3):144-51.
259. Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program. *Drug Alcohol Depend*. 2010;107(2-3):237-43.
260. Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. *Nicotine Tob Res*. 2013;15(2):348-54.
261. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. *JAMA Intern Med*. 2015;175(4):504-11.
262. Schnoll R, Leone F, Veluz-Wilkins A, Miele A, Hole A, Jao NC, et al. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. *Psychooncology*. 2019;28(3):561-9.
263. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. *Addiction*. 2004;99(5):634-40.
264. Selby P BBSN. Retreatment with ZYban SR: 52 week follow-up of a Canadian Multicentre trial (POS3-63). 2003.
265. Selma Bozkurt Z, Serkan Z, Esra K, Esra Aydin S. Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program. *Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology*. 2013;23(3):224-30.
266. Severson HH, Danaher BG, Ebbert JO, van Meter N, Lichtenstein E, Widdop C, et al. Randomized trial of nicotine lozenges and phone counseling for smokeless tobacco cessation. *Nicotine Tob Res*. 2015;17(3):309-15.
267. Sharma SK, Mohan A, Singh AD, Mishra H, Jhanjee S, Pandey RM, et al. Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. *Sci Rep*. 2018;8(1):8828.
268. Sheng LX, Tang YL, Jiang ZN, Yao CH, Gao JY, Xu GZ, et al. Sustained-release bupropion for smoking cessation in a Chinese sample: a double-blind, placebo-controlled, randomized trial. *Nicotine Tob Res*. 2013;15(2):320-5.
269. Sherman SE, Aldana I, Estrada M, York L. Comparing the tolerability and effectiveness of two treatment regimens in a smoking clinic. *Mil Med*. 2008;173(6):550-4.
270. Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*. 2002;162(11):1267-76.
271. Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, et al. Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers. *J Consult Clin Psychol*. 2006;74(2):276-85.
272. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. *Am J Prev Med*. 2009;36(2):96-104 e1.
273. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. *Neuropsychopharmacology*. 2012;37(3):660-8.
274. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug Alcohol Depend*. 2008;96(3):222-32.
275. Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. *Ann Intern Med*. 2013;158(9):667-75.
276. Simon JA, Solkowitz SN, Carmody TP, Browner WS. Smoking cessation after surgery. A randomized trial. *Arch Intern Med*. 1997;157(12):1371-6.
277. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. *Arch Intern Med*. 2004;164(16):1797-803.
278. Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial. *Nicotine Tob Res*. 2009;11(6):663-9.
279. Singh P, Kumar R. Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation. *Lung India*. 2010;27(1):11-8.
280. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med*. 2009;169(22):2148-55.
281. Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. *PLoS One*. 2016;11(1):e0143490.
282. ZYB40005: The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking.
283. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. *American Journal of Epidemiology*. 1997;145(4):309-18.
284. Sorensen LT, Jorgensen T. Short-term pre-operative smoking cessation intervention does not affect postoperative complications in colorectal surgery: a randomized clinical trial. *Colorectal Dis*. 2003;5(4):347-52.
285. Southern Illinois University Carbondale, National Institute on Drug Abuse. Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers. <https://ClinicalTrials.gov/show/NCT01048944>; 2005.
286. Stanford University, Pfizer. Varenicline In-Patient Study. <https://ClinicalTrials.gov/show/NCT01413516>; 2011.
287. Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. *Addiction*. 1995;90(1):31-42.
288. Stapleton JA, Sutherland G. Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. *Addiction*. 2011;106(4):824-32.
289. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. *Addiction*. 2013;108(12):2193-201.
290. Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. *Drug Alcohol Depend*. 2013;133(2):486-93.
291. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. *Ann Intern Med*. 2009;150(7):447-54.
292. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. *Addict Behav*. 2011;36(12):1127-32.
293. Steinberg ML, Lu SE, Williams JM. Varenicline for smoking reduction in smokers not yet ready to quit: A double-blind, proof-of-concept randomized clinical trial. *Addict Behav*. 2018;84:20-6.
294. Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, et al. Randomized Controlled Trial of Nasal Nicotine Spray in Smoking Cessation. *Lancet*. 1992;340(8815):324-9.
295. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. *Arch Intern Med*. 2003;163(19):2337-44.
296. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet*. 2001;357(9268):1571-5.
297. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest*. 2011;139(3):591-9.
298. Thomsen T, Tonnesen H, Okholm M, Kroman N, Maibom A, Sauerberg ML, et al. Brief smoking cessation intervention in relation to breast cancer surgery: a randomized controlled trial. *Nicotine Tob Res*. 2010;12(11):1118-24.

299. Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. *Neuropsychopharmacology*. 2001;24(4):350-8.
300. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. *Psychopharmacology (Berl)*. 2011;217(2):279-87.
301. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnarsen AB, Forchammer H, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. *N Engl J Med*. 1988;318(1):15-8.
302. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnarsen AB, Forchammer H, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. *Addict Behav*. 1988;13(1):17-27.
303. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *N Engl J Med*. 1991;325(5):311-5.
304. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA*. 1993;269(10):1268-71.
305. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. *European Respiratory Society. Eur Respir J*. 1999;13(2):238-46.
306. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J*. 2000;16(4):717-22.
307. Tonnesen P, Tonstad S, Hjalmarson A, Leborgy F, Van Spiegel PI, Hider A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. *J Intern Med*. 2003;254(2):184-92.
308. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest*. 2006;130(2):334-42.
309. Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. *Eur Respir J*. 2012;40(3):548-54.
310. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J*. 2003;24(10):946-55.
311. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):64-71.
312. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Jr., et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther*. 2007;29(6):1027-39.
313. Tseng TY, Ostroff JS, Campo A, Gerard M, Kirchner T, Rotrosen J, et al. A Randomized Trial Comparing the Effect of Nicotine Versus Placebo Electronic Cigarettes on Smoking Reduction Among Young Adult Smokers. *Nicotine Tob Res*. 2016;18(10):1937-43.
314. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). *Circ J*. 2010;74(4):771-8.
315. Tuisku A, Salmela M, Nieminen P, Toljamo T. Varenicline and Nicotine Patch Therapies in Young Adults Motivated to Quit Smoking: A Randomized, Placebo-controlled, Prospective Study. *Basic Clin Pharmacol Toxicol*. 2016;119(1):78-84.
316. Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. *BMC Med*. 2016;14(80):80.
317. Tzivoni D, Keren A, Meyler S, Khoury Z, Lerer T, Brunel P. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. *Cardiovasc Drugs Ther*. 1998;12(3):239-44.
318. University of Michigan, National Heart LaBI. A Randomized Trial of Internet Access to Nicotine Patches. <https://ClinicalTrials.gov/show/NCT00534404>; 2011.
319. Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A, et al. A randomized trial of smoking cessation. Medication versus motivation. *Saudi Med J*. 2007;28(6):922-6.
320. Velicer WF, Friedman RH, Fava JL, Gulliver SB, Keller S, Sun X, et al. Evaluating nicotine replacement therapy and stage-based therapies in a population-based effectiveness trial. *J Consult Clin Psychol*. 2006;74(6):1162-72.
321. Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. *J Addict Med*. 2016;10(3):166-73.
322. Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM, Schayck CPR. Efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: Results from a randomized, placebo-controlled trial. *Nicotine & Tobacco Research*. 2005;7(4):683-4.
323. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction*. 2000;95(8):1161-71.
324. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. *Respirology*. 2009;14(3):384-92.
325. Ward KD, Asfar T, Al Ali R, Rastam S, Weg MW, Eissenberg T, et al. Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics. *Addiction*. 2013;108(2):394-403.
326. Warner DO, Patten CA, Ames SC, Offord KP, Schroeder DR. Effect of nicotine replacement therapy on stress and smoking behavior in surgical patients. *Anesthesiology*. 2005;102(6):1138-46.
327. Weaver K, Kaplan S, Urbanic J, Case D, Zbikowski S, Dakhil C, et al. Incorporating evidence-based smoking cessation into community oncology practices: Feasibility and preliminary efficacy of an enhanced quitline-based smoking cessation intervention for cancer survivors 2015; 24:[32 p.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/1471-2575.1234>.
328. Weinberger AH, Vessicchio JC, Sacco KA, Creeden CL, Chengappa KN, George TP. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. *J Clin Psychopharmacol*. 2008;28(5):584-7.
329. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. *Schizophr Res*. 2011;129(1):94-5.
330. Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. *J Clin Psychiatry*. 2012;73(1):95-102.
331. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. *Addiction*. 2003;98(10):1395-402.
332. Westergaard CG, Porsbjerg C, Backer V. The effect of Varenicline on smoking cessation in a group of young asthma patients. *Respir Med*. 2015;109(11):1416-22.
333. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. *Arch Intern Med*. 1993;153(16):1917-23.
334. Whelton H, Kingston R, O'Mullane D, Nilsson F. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. *BMC Oral Health*. 2012;12(13):13.
335. Wiggers LC, Smets EM, Oort FJ, Peters RJ, Storm-Versloot MN, Vermeulen H, et al. The effect of a minimal intervention strategy in addition to nicotine replacement therapy to support smoking cessation in cardiovascular outpatients: a randomized clinical trial. *Eur J Cardiovasc Prev Rehabil*. 2006;13(6):931-7.
336. Williams KE, Reeves KR, Billing CB, Jr., Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr Med Res Opin*. 2007;23(4):793-801.
337. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry*. 2012;73(5):654-60.
338. Wilson JS, Fitzsimons D, Bradbury I, Stuart Elborn J. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. *Int J Nurs Stud*. 2008;45(4):508-17.
339. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, Penn P, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. *J Clin Psychiatry*. 2014;75(4):336-43.
340. Wiratmoko MR, Yunus F, Susanto AD, Ginting TT, Kekalih A. Efficacy of Varenicline, an Nicotinic Acetylcholine Receptor Partial Agonist, Vs Placebo for Smoking Cessation. A Randomized Controlled Trial. *Respirology*. 2013;18:66-.

341. Wittchen HU, Hoch E, Klotsche J, Muehlig S. Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention. *Int J Methods Psychiatr Res.* 2011;20(1):28-39.
342. Wolfenden L, Wiggers J, Knight J, Campbell E, Rissel C, Kerridge R, et al. A programme for reducing smoking in pre-operative surgical patients: randomised controlled trial. *Anaesthesia.* 2005;60(2):172-9.
343. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. *Addiction.* 1999;94(8):1227-37.
344. Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. *Anesthesiology.* 2012;117(4):755-64.
345. Wong J, Abrishami A, Riazi S, Siddiqui N, You-Ten E, Korman J, et al. A Perioperative Smoking Cessation Intervention With Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. *Anesth Analg.* 2017;125(2):571-9.
346. Yale University, National Institute on Alcohol Abuse and Alcoholism. The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior. <https://ClinicalTrials.gov/show/NCT00580853>; 2007.
347. Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals. *Am J Health Behav.* 2005;29(3):240-9.
348. Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. *Addiction.* 2008;103(12):2024-31.
349. Zhu J. The effectiveness of bupropion SR on depressive symptoms in smokers: Self-reports, EEG, and individual differences. *Dissertation Abstracts International: Section B: The Sciences and Engineering.* 2016;77(3-B(E)):No Pagination Specified.
350. ZYB40030: a multi-centre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release versus placebo as an aid to smoking cessation in a population of smokers with chronic obstructive pulmonary disease.
351. ZYB 30011:A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor.
352. SMK20001:A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation.